


SignPath Pharma Inc - Product Pipeline Review - 2015































| Compare 
About Us | 
Contact Us






Home
Research Category
Publisher List
Custom Research
Cart
Compare



Research Category
User Guide
Policies
Contact Us
About us
Site Map











Home > Market Research Report  > Pharmaceutical > Pharmaceutical Companies > Pharma Info









Market Research Report
SignPath Pharma Inc - Product Pipeline Review - 2015



Published by
Global Markets Direct
Product code
308911


Published
July 8, 2015
Content info
27 Pages 


Price








USD 1500

PDF by E-mail (Single user license)





USD 3000

PDF by E-mail (Site license)





USD 4500

PDF by E-mail (Global license)
























SignPath Pharma Inc - Product Pipeline Review - 2015



Published: July 8, 2015
Content info: 27 Pages














Description

Summary
Global Markets Direct's, 'SignPath Pharma Inc - Product Pipeline Review - 2015', provides an overview of the SignPath Pharma Inc's pharmaceutical research and development focus.
This report provides comprehensive information on the current therapeutic developmental pipeline of SignPath Pharma Inc's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.
Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope

 The report provides brief overview of SignPath Pharma Inc including business description, key information and facts, and its locations and subsidiaries
 The report reviews current pipeline of SignPath Pharma Inc's human therapeutic division and enlists all their major and minor projects
 The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
 Special feature on out-licensed and partnered product portfolio
 The report summarizes all the dormant and discontinued pipeline projects
 Latest company statement
 Latest news and deals relating to the SignPath Pharma Inc's pipeline products

Reasons to buy

 Evaluate SignPath Pharma Inc's strategic position with total access to detailed information on its product pipeline
 Assess the growth potential of SignPath Pharma Inc in its therapy areas of focus
 Identify new drug targets and therapeutic classes in the SignPath Pharma Inc's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
 Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
 Develop strategic initiatives by understanding the focus areas of SignPath Pharma Inc and exploit collaboration and partnership opportunities
 Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
 Plan mergers and acquisitions effectively by identifying the most promising pipeline of SignPath Pharma Inc
 Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
 Explore the dormant and discontinued projects of SignPath Pharma Inc and identify potential opportunities in those areas
 Avoid Intellectual Property Rights related issues




Table of Contents
Product Code: GMDHC07352CDBTable of Contents

Table of Contents 

List of Tables 
List of Figures 

SignPath Pharma Inc Snapshot 

SignPath Pharma Inc Overview 
Key Information 
Key Facts 

SignPath Pharma Inc - Research and Development Overview 

Key Therapeutic Areas 

SignPath Pharma Inc - Pipeline Review 

Pipeline Products by Stage of Development 
Pipeline Products - Monotherapy 

SignPath Pharma Inc - Pipeline Products Glance 

SignPath Pharma Inc - Clinical Stage Pipeline Products 

Phase I Products/Combination Treatment Modalities 

SignPath Pharma Inc - Early Stage Pipeline Products 

IND/CTA Filed Products/Combination Treatment Modalities 
Preclinical Products/Combination Treatment Modalities 


SignPath Pharma Inc - Drug Profiles 

Liposomal Curcumin 

Product Description 
Mechanism of Action 
R&D Progress

EU-8120 

Product Description 
Mechanism of Action 
R&D Progress

Liposomal PLGA Curcumin 

Product Description 
Mechanism of Action 
R&D Progress

Nanocurcumin 

Product Description 
Mechanism of Action 
R&D Progress


SignPath Pharma Inc - Pipeline Analysis 

SignPath Pharma Inc - Pipeline Products by Target 
SignPath Pharma Inc - Pipeline Products by Route of Administration 
SignPath Pharma Inc - Pipeline Products by Molecule Type 
SignPath Pharma Inc - Pipeline Products by Mechanism of Action 

SignPath Pharma Inc - Recent Pipeline Updates 
SignPath Pharma Inc - Dormant Projects 
SignPath Pharma Inc - Locations And Subsidiaries 

Head Office 

Appendix 

Methodology 
Coverage 
Secondary Research 
Primary Research 
Expert Panel Validation 
Contact Us 
Disclaimer 


List of Tables

SignPath Pharma Inc, Key Information 
SignPath Pharma Inc, Key Facts 
SignPath Pharma Inc - Pipeline by Indication, 2015 
SignPath Pharma Inc - Pipeline by Stage of Development, 2015 
SignPath Pharma Inc - Monotherapy Products in Pipeline, 2015 
SignPath Pharma Inc - Phase I, 2015 
SignPath Pharma Inc - IND/CTA Filed, 2015 
SignPath Pharma Inc - Preclinical, 2015 
SignPath Pharma Inc - Pipeline by Target, 2015 
SignPath Pharma Inc - Pipeline by Route of Administration, 2015 
SignPath Pharma Inc - Pipeline by Molecule Type, 2015 
SignPath Pharma Inc - Pipeline Products by Mechanism of Action, 2015 
SignPath Pharma Inc - Recent Pipeline Updates, 2015 
SignPath Pharma Inc - Dormant Developmental Projects,2015 

List of Figures

SignPath Pharma Inc - Pipeline by Top 10 Indication, 2015 
SignPath Pharma Inc - Pipeline by Stage of Development, 2015 
SignPath Pharma Inc - Monotherapy Products in Pipeline, 2015 
SignPath Pharma Inc - Pipeline by Top 10 Route of Administration, 2015 
SignPath Pharma Inc - Pipeline by Top 10 Molecule Type, 2015 








Phone


Int'l: +1-860-674-8796
TollFree(US): +1-866-353-3335
Europe: +32-2-535-7543
Asia: +65-6223-2436


New for 2017 !

GII now purchases any market research reports from any publishers for you.  
			With noextra cost.
Contact us for more details.

FAQ


Delivery Time
User License
Payment Options
Compare Multiple Reports
















About
Contact
User Guide
Policies
Site Map



© Copyright 1997-2017, Global Information, Inc. All rights reserved.






Pharmaceuticals Market Research Reports on Market Size and Competitive Analysis











































Advanced search


1 888 391 5441

sales@rnrmarketresearch.com


Search Market Research Reports






 Market Research Assistance+ 1-888-391-5441sales@rnrmarketresearch.comOn the Web       

Refine ResultBy DateLast MonthLast 3 MonthsLast 6 MonthsLast YearLast 2 Years
By Price< $1000$1000-$2500$2501-$4000$4001-$5500$5501-$7500$7501-$9000>$9000





Home
  >  Life Sciences  >  Pharmaceuticals 




Pharmaceuticals Market Research Reports 

 

The global pharmaceutical market has persistently experienced significant growth due to the ever-increasing demand for novel and more effective drugs. The reasons for this steady increase in the demand for drugs worldwide can be attributed to population growth, newer and more complex disease conditions, ageing population, and the increased prevalence of chronic and infectious diseases, some of which still remain incurable and fatal. Such numerous unmet needs and high demand rates have triggered the boost in R&D investments by key industry sectors, greatly driving the growth of this industry. The pharmaceutical market, valued as a multi-billion dollar market, is undoubtedly the largest revenue generator for the life sciences industry.

The pharmaceutical industry can be divided into numerous market segments based on the different therapeutic areas and applications. The largest segment, the market for cardiovascular drugs, records huge sales every year. The rising world population, rap...View More
The global pharmaceutical market has persistently experienced significant growth due to the ever-increasing demand for novel and more effective drugs. The reasons for this steady increase in the demand for drugs worldwide can be attributed to population growth, newer and more complex disease conditions, ageing population, and the increased prevalence of chronic and infectious diseases, some of which still remain incurable and fatal. Such numerous unmet needs and high demand rates have triggered the boost in R&D investments by key industry sectors, greatly driving the growth of this industry. The pharmaceutical market, valued as a multi-billion dollar market, is undoubtedly the largest revenue generator for the life sciences industry.

The pharmaceutical industry can be divided into numerous market segments based on the different therapeutic areas and applications. The largest segment, the market for cardiovascular drugs, records huge sales every year. The rising world population, rapid ageing of the same, and an increased prevalence of diseases are the major factors driving growth of this industry. The recent breakthroughs in proteomics and genomics have led to the development of modernized approaches to drug discovery and development in the industry, for the possibility of newer, advanced, and more sophisticated therapies and drugs. Developments in biotechnology research have led to introduction of advanced therapies involving biopharmaceuticals, regenerative medicine, stem cells, etc. These new age therapies and products have caused ease of treatment procedures and enabled speedy recovery from various disorders. Technological growth in such interdisciplinary fields has opened up new arenas in drug discovery, drug delivery, and life sciences research.View Less


TherapeuticsDiseases & treatmentClinical TrialDietary SupplementsBiopharmaceuticalsPharmaceutical PackagingPain ManagementPandemic VaccineBiosimilarPharmaceutical DistributionOver The Counter (OTC) DrugAnesthesia DrugsCancer VaccinePharmaceutical TechnologyRadiopharmaceuticalPrescription DrugsPharmaceutical DetailingClinical Nutrition

Pharmaceuticals Market Research Reports 

Titlepublishedprice

2017-2022 Global and Japan Hypolipidemic drugs Market Analysis ReportBy QYResearch Group"...... e xx million USD in 2022, with a CAGR of xx%. 

This report studies the Hypolipidemic drugs development status and future trend in Japan, focuses on top players in Japan, also splits Hypolipidemic drugs by type and by applications, to f......"28-Jul-2017$3085

Global and Europe Bacillus Subtilis Market - Analysis and Outlook to 2022By QYResearch Group"......  players, growth and demand drivers, etc. As a Detailed Analysis report, it covers all details inside analysis and opinion in Bacillus Subtilis industry. 

This report focus Global and Europe market, it covers details players regions pr......"28-Jul-2017$2960

Global and Europe Antipsychotic drugs Market - Analysis and Outlook to 2022By QYResearch Group"...... rs, growth and demand drivers, etc. As a Detailed Analysis report, it covers all details inside analysis and opinion in Antipsychotic drugs industry.
This report focus Global and Europe market, it covers details players regions product type an......"28-Jul-2017$2960

Asia-Pacific Vitamin & Mineral Supplement Market by Manufacturers, Regions, Type and Application, Forecast to 2022By Global Info Research"...... mins are stored in the body's cells and do not pass out of the body as easily as water-soluble vitamins do. Fat-soluble vitamins include vitamins A, D, E, and K.
Minerals. These include calcium, copper, iron, magnesium, phosphorus, potassium, ......"28-Jul-2017$4480

Asia-Pacific Pressure Ulcer Treatment Products Market by Manufacturers, Regions, Type and Application, Forecast to 2022By Global Info Research"...... sore. Pressure ulcer commonly occur on the elbows, back of the head, buttocks, heels, shoulders, hips, ankles, and back. 

Scope of the Report:
This report focuses on the Pressure Ulcer Treatment Products in Asia-Pacific market, ......"28-Jul-2017$4480

Asia-Pacific Narcolepsy Drug Market by Manufacturers, Regions, Type and Application, Forecast to 2022By Global Info Research"...... of muscle strength, known as cataplexy. These spells can be brought on by strong emotions. Less commonly, there may be inability to move or vivid hallucinations while falling asleep or waking up. People with narcolepsy tend to sleep about the same nu......"28-Jul-2017$4480

Asia-Pacific Maca Extract Market by Manufacturers, Regions, Type and Application, Forecast to 2022By Global Info Research"...... sed in many of the best male enhancement pills. Maca root extract is contained in many leading male enhancement supplements and is widely used to treat hot flushes, memory loss, stress, depression and fertility. 

Scope of the Report:......"28-Jul-2017$4480

Asia-Pacific Lipoic Acid Market by Manufacturers, Regions, Type and Application, Forecast to 2022By Global Info Research"...... into a- lipoic acid (alpha lipoic acid), R- lipoic acid and S- lipoic acid. Common commercially available lipoic acid are alpha lipoic acid, so in the report, the volume of lipoic acid is calculated by alpha lipoic acid."

Scope of the ......"28-Jul-2017$4480

Global Antipsychotic drugs Detailed Analysis Report 2017-2022By QYResearch Group"......  regions, by product type, by consumers and also their price change details. As a Detailed Analysis report, it covers all details inside analysis and opinion in Antipsychotic drugs industry.

This report focus Global market, it covers d......"28-Jul-2017$3250

Global Sodium Hyaluronate Market Professional Survey Report 2017By QYResearch Group"...... turers in global market, with production, price, revenue and market share for each manufacturer, covering
- Contipro
- Lifecore Biomedical
- SEIKAGAKU Corporation
- VSY Biotechnology
- Fidia Farmaceutici S.p.A......"27-Jul-2017$3500
 
1 | 2 | 3 | 4 | 5 | 6 | 7 | ...3398 | 3399next »

 








 Avail upto 25% Discount on below Publisher Reports.
   
Azoth Analytics 
Technavio
























Bing Places for Business
























































































































Bing
 places for business


Sign in using your




Microsoft Account





Work Account





Google Account





Facebook Account

Don't have an account? Create one.





Microsoft personalized ad preferences




 













To opt out of personalized ads in this browser, your browser history must allow first-party and third-party cookies and you must have your browsing experience set to NOT delete browsing history on exit. Instructions for enabling cookies and configuring your browsing history may be available in your browsers settings, privacy, or help documentation.

















Sign in
















  Hold on… We’re sorry but this didn’t work.                  You can’t turn off personalized ads right now because your browser is currently blocking third-party cookies. We can help you fix this issue.                Let’s get started:  Depending on what browser you use, open Options or Settings.                  Make sure that third-party cookies are not blocked anymore. To find out how, search your browser’s Help.                                 Revisit http://choice.microsoft.com/opt-out, and then on the “Personalized ads in this browser” tile, click Off.                 ext74081 




  About Our Ads To create a more customized online experience, some of the ads you may receive on Microsoft websites and apps are tailored to your previous activities, searches and site visits. You're in control and here's where you can make the advertising choice that's right for you. ext74075 




  Where Can I Learn More about Advertising on Microsoft Websites and Apps? Microsoft partners with Oath, AppNexus and other third party service providers to help present customized content and display advertisements on MSN, Outlook.com and other websites and apps. Microsoft also delivers search ads to Bing and our search syndication partners. Learn more about Microsoft’s privacy practices here. You can learn more about interest-based ads from Oath and AppNexus in their privacy statements: Oath and AppNexus. What Choices Do I Have About Interest-Based Advertising? On this page, you can opt out of receiving interest based advertising from Microsoft. You can also opt out of receiving interest-based advertising from all self-regulatory members, including Microsoft, Oath, AppNexus and other third party ad networks, at the following sites:  In the US: Digital Advertising Alliance (DAA) In Europe: European Interactive Digital Advertising Alliance (EDAA) In Canada: Ad Choices: Digital Advertising Alliance of Canada (DAAC)  You can control interest-based advertising in Windows apps by turning off the advertising ID in Windows Settings.  More choices  Do you want personalized ads from other companies?  Questions? If you have a privacy question or a question for the Chief Privacy Officer of Microsoft, please contact us by using our web form. We will respond to questions within 30 days. ext74076 




       Personalized ads in this browser     OFF    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting for this web browser.  Learn more           If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.          ext74078 




       Personalized ads wherever I use my Microsoft account     OFF   Sign in to change...    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting that applies when you are signed in on any computer or device with your Microsoft account, including Windows, Windows phone, Xbox and other devices.  Learn more                    If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.         If you choose “generic” ads and use a browser, your choice applies to everyone when using that browser as long as you do not clear your cookies.          ext74079 




       Personalized ads in Windows         In your Windows Settings, you can turn off personalized ads that appear in apps on this device. You’ll still see ads, but they won’t be personalized anymore.     If you have Windows 8.1:            Access the charms by touching or moving your pointer to the right edge of the screen.                 Click or tap Settings, and then click or tap Change PC Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have Windows 10:            Click or tap the Start button.                 Click or tap Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have a Windows mobile device:            Go to Settings.                 Tap on Privacy.                 Tap on Advertising ID, and then turn off Let apps use my advertising ID for experiences across apps.                If you want to turn off personalized ads from Microsoft wherever you use your Microsoft account including apps on Windows, Windows Phone, Xbox and other devices, you can do so by selecting the Microsoft account option above.    ext74080 














Legal
Privacy & Cookies
© 2017 Microsoft














SignPath Pharma Inc - Product Pipeline Review - 2015

























 info@marketreportscenter.com
 +1-646-883-3044 (US) 24x7















LOGIN
SIGN UP














Facebook



Twitter



LinkedIn



Google +



MRC Blog



YouTube







SignPath Pharma Inc - Product Pipeline Review - 2015

Home >> Pharmaceuticals >> Global Markets Direct >> SignPath Pharma Inc - Product Pipeline Review - 2015



Report Details





SignPath Pharma Inc - Product Pipeline Review - 2015







SKU
GMDJUL081575


Category
Pharmaceuticals


Publisher
Global Markets Direct


Pages
27


Published
Jul-15





SKUGMDJUL081575
CategoryPharmaceuticals
PublisherGlobal Markets Direct
Pages27
Published OnJul-15

Request Discount
Pay by Wire/Invoice





Description
Table of Content
List of Figures
Request Sample




Description
SignPath Pharma Inc - Product Pipeline Review - 2015

Summary

Global Markets Directs, SignPath Pharma Inc - Product Pipeline Review - 2015, provides an overview of the SignPath Pharma Incs pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of SignPath Pharma Incs, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of SignPath Pharma Inc including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of SignPath Pharma Incs human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the SignPath Pharma Incs pipeline products

Reasons to buy

- Evaluate SignPath Pharma Incs strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of SignPath Pharma Inc in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the SignPath Pharma Incs R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of SignPath Pharma Inc and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of SignPath Pharma Inc
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of SignPath Pharma Inc and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

News/Press Release

Precision Medicine: How the life science industry can improve outcomes through To achieve successful precision medicine at scale and to be able to offer it as an everyday treatment option, researchers in drug R&D need to better understand and manage the reams of unstructured dat...Read More
Regenerative Medicine Market to Hit $53 billion by 2021 The current regenerative medicine market is worth $18.9 billion globally, and will hit over $53 billion by 2021, as impact of Trump administration....Read More
7 Benefits of MicroneedlingMicroneedling: Hundreds of tiny pin pricks going into your skin might sound weird but it could just be the best thing that ever happened to your face....Read More



Table of Content
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
SignPath Pharma Inc Snapshot 5
SignPath Pharma Inc Overview 5
Key Information 5
Key Facts 5
SignPath Pharma Inc - Research and Development Overview 6
Key Therapeutic Areas 6
SignPath Pharma Inc - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
SignPath Pharma Inc - Pipeline Products Glance 10
SignPath Pharma Inc - Clinical Stage Pipeline Products 10
Phase I Products/Combination Treatment Modalities 10
SignPath Pharma Inc - Early Stage Pipeline Products 11
IND/CTA Filed Products/Combination Treatment Modalities 11
Preclinical Products/Combination Treatment Modalities 12
SignPath Pharma Inc - Drug Profiles 13
Liposomal Curcumin 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
EU-8120 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
Liposomal PLGA Curcumin 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
Nanocurcumin 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
SignPath Pharma Inc - Pipeline Analysis 19
SignPath Pharma Inc - Pipeline Products by Target 19
SignPath Pharma Inc - Pipeline Products by Route of Administration 20
SignPath Pharma Inc - Pipeline Products by Molecule Type 21
SignPath Pharma Inc - Pipeline Products by Mechanism of Action 22
SignPath Pharma Inc - Recent Pipeline Updates 23
SignPath Pharma Inc - Dormant Projects 24
SignPath Pharma Inc - Locations And Subsidiaries 25
Head Office 25
Appendix 26
Methodology 26
Coverage 26
Secondary Research 26
Primary Research 26
Expert Panel Validation 26
Contact Us 26
Disclaimer 27


List of Figures
List of Tables
SignPath Pharma Inc, Key Information 5
SignPath Pharma Inc, Key Facts 5
SignPath Pharma Inc - Pipeline by Indication, 2015 7
SignPath Pharma Inc - Pipeline by Stage of Development, 2015 8
SignPath Pharma Inc - Monotherapy Products in Pipeline, 2015 9
SignPath Pharma Inc - Phase I, 2015 10
SignPath Pharma Inc - IND/CTA Filed, 2015 11
SignPath Pharma Inc - Preclinical, 2015 12
SignPath Pharma Inc - Pipeline by Target, 2015 19
SignPath Pharma Inc - Pipeline by Route of Administration, 2015 20
SignPath Pharma Inc - Pipeline by Molecule Type, 2015 21
SignPath Pharma Inc - Pipeline Products by Mechanism of Action, 2015 22
SignPath Pharma Inc - Recent Pipeline Updates, 2015 23
SignPath Pharma Inc - Dormant Developmental Projects,2015 24
List of Figures
SignPath Pharma Inc - Pipeline by Top 10 Indication, 2015 7
SignPath Pharma Inc - Pipeline by Stage of Development, 2015 8
SignPath Pharma Inc - Monotherapy Products in Pipeline, 2015 9
SignPath Pharma Inc - Pipeline by Top 10 Route of Administration, 2015 20
SignPath Pharma Inc - Pipeline by Top 10 Molecule Type, 2015 21







Please Select License Type






Single User Electronic PDF 
$ 1,500.00


Site User Electronic PDF 
$ 3,000.00


Enterprise Wide Electronic PDF 
$ 4,500.00



ADD TO CART

BUY NOW






Related Reports




 Global Incoloy Alloy MA 956 Sales Market Report 2017 Global Zinc Dimethyldithiocarbamate Market Research Report 2017 Global Grate Bars for Refuse Incinerators Industry Report 2012-2022 Global and Chinese zinc trifluoromethanesulphonate (CAS 54010-75-2) Industry, 2017 Market Research Report Global and Chinese Zinc Fumarate (CAS 52723-61-2) Industry, 2017 Market Research Report 










Request Sample






Mr
Mrs
Ms
Dr






















Afghanistan (+93)
Albania (+355)
Algeria (+213)
Andorra (+376)
Angola (+244)
Antigua and Barbuda (+-267)
Argentina (+54)
Armenia (+374)
Australia (+61)
Austria (+43)
Azerbaijan (+994)
Bahamas, The (+-241)
Bahrain (+973)
Bangladesh (+880)
Barbados (+-245)
Belarus (+375)
Belgium (+32)
Belize (+501)
Benin (+229)
Bhutan (+975)
Bolivia (+591)
Bosnia and Herzegovina (+387)
Botswana (+267)
Brazil (+55)
Brunei (+673)
Bulgaria (+359)
Burkina Faso (+226)
Burundi (+257)
Cambodia (+855)
Cameroon (+237)
Canada (+1)
Cape Verde (+238)
Central African Republic (+236)
Chad (+235)
Chile (+56)
China, People's Republic of (+86)
Colombia (+57)
Comoros (+269)
Congo, (Congo  Kinshasa) (+243)
Congo, (Congo  Brazzaville) (+242)
Costa Rica (+506)
Cote d'Ivoire (Ivory Coast) (+225)
Croatia (+385)
Cuba (+53)
Cyprus (+357)
Czech Republic (+420)
Denmark (+45)
Djibouti (+253)
Dominica (+-766)
Dominican Republic (++1-809 and 1-829)
Ecuador (+593)
Egypt (+20)
El Salvador (+503)
Equatorial Guinea (+240)
Eritrea (+291)
Estonia (+372)
Ethiopia (+251)
Fiji (+679)
Finland (+358)
France (+33)
Gabon (+241)
Gambia, The (+220)
Georgia (+995)
Germany (+49)
Ghana (+233)
Greece (+30)
Grenada (+-472)
Guatemala (+502)
Guinea (+224)
Guinea-Bissau (+245)
Guyana (+592)
Haiti (+509)
Honduras (+504)
Hungary (+36)
Iceland (+354)
India (+91)
Indonesia (+62)
Iran (+98)
Iraq (+964)
Ireland (+353)
Israel (+972)
Italy (+39)
Jamaica (+-875)
Japan (+81)
Jordan (+962)
Kazakhstan (+7)
Kenya (+254)
Kiribati (+686)
Korea, North (+850)
Korea, South (+82)
Kuwait (+965)
Kyrgyzstan (+996)
Laos (+856)
Latvia (+371)
Lebanon (+961)
Lesotho (+266)
Liberia (+231)
Libya (+218)
Liechtenstein (+423)
Lithuania (+370)
Luxembourg (+352)
Macedonia (+389)
Madagascar (+261)
Malawi (+265)
Malaysia (+60)
Maldives (+960)
Mali (+223)
Malta (+356)
Marshall Islands (+692)
Mauritania (+222)
Mauritius (+230)
Mexico (+52)
Micronesia (+691)
Moldova (+373)
Monaco (+377)
Mongolia (+976)
Montenegro (+382)
Morocco (+212)
Mozambique (+258)
Myanmar (Burma) (+95)
Namibia (+264)
Nauru (+674)
Nepal (+977)
Netherlands (+31)
New Zealand (+64)
Nicaragua (+505)
Niger (+227)
Nigeria (+234)
Norway (+47)
Oman (+968)
Pakistan (+92)
Palau (+680)
Panama (+507)
Papua New Guinea (+675)
Paraguay (+595)
Peru (+51)
Philippines (+63)
Poland (+48)
Portugal (+351)
Qatar (+974)
Romania (+40)
Russia (+7)
Rwanda (+250)
Saint Kitts and Nevis (+-868)
Saint Lucia (+-757)
Saint Vincent and the Grenadines (+-783)
Samoa (+685)
San Marino (+378)
Sao Tome and Principe (+239)
Saudi Arabia (+966)
Senegal (+221)
Serbia (+381)
Seychelles (+248)
Sierra Leone (+232)
Singapore (+65)
Slovakia (+421)
Slovenia (+386)
Solomon Islands (+677)
Somalia (+252)
South Africa (+27)
Spain (+34)
Sri Lanka (+94)
Sudan (+249)
Suriname (+597)
Swaziland (+268)
Sweden (+46)
Switzerland (+41)
Syria (+963)
Tajikistan (+992)
Tanzania (+255)
Thailand (+66)
Timor-Leste (East Timor) (+670)
Togo (+228)
Tonga (+676)
Trinidad and Tobago (+-867)
Tunisia (+216)
Turkey (+90)
Turkmenistan (+993)
Tuvalu (+688)
Uganda (+256)
Ukraine (+380)
United Arab Emirates (+971)
United Kingdom (+44)
United States (+1)
Uruguay (+598)
Uzbekistan (+998)
Vanuatu (+678)
Vatican City (+379)
Venezuela (+58)
Vietnam (+84)
Yemen (+967)
Zambia (+260)
Zimbabwe (+263)
Abkhazia (+995)
China, Republic of (Taiwan) (+886)
Nagorno-Karabakh (+277)
Northern Cyprus (+-302)
Pridnestrovie (Transnistria) (+-160)
Somaliland (+252)
South Ossetia (+995)
Ashmore and Cartier Islands (+)
Christmas Island (+61)
Cocos (Keeling) Islands (+61)
Coral Sea Islands (+)
Heard Island and McDonald Islands (+)
Norfolk Island (+672)
New Caledonia (+687)
French Polynesia (+689)
Mayotte (+262)
Saint Barthelemy (+590)
Saint Martin (+590)
Saint Pierre and Miquelon (+508)
Wallis and Futuna (+681)
French Southern and Antarctic Lands (+)
Clipperton Island (+)
Bouvet Island (+)
Cook Islands (+682)
Niue (+683)
Tokelau (+690)
Guernsey (+44)
Isle of Man (+44)
Jersey (+44)
Anguilla (+-263)
Bermuda (+-440)
British Indian Ocean Territory (+246)
British Sovereign Base Areas (+357)
British Virgin Islands (+-283)
Cayman Islands (+-344)
Falkland Islands (Islas Malvinas) (+500)
Gibraltar (+350)
Montserrat (+-663)
Pitcairn Islands (+)
Saint Helena (+290)
South Georgia & South Sandwich Islands (+)
Turks and Caicos Islands (+-648)
Northern Mariana Islands (+-669)
Puerto Rico (++1-787 and 1-939)
American Samoa (+-683)
Baker Island (+)
Guam (+-670)
Howland Island (+)
Jarvis Island (+)
Johnston Atoll (+)
Kingman Reef (+)
Midway Islands (+)
Navassa Island (+)
Palmyra Atoll (+)
U.S. Virgin Islands (+-339)
Wake Island (+)
Hong Kong (+852)
Macau (+853)
Faroe Islands (+298)
Greenland (+299)
French Guiana (+594)
Guadeloupe (+590)
Martinique (+596)
Reunion (+262)
Aland (+340)
Aruba (+297)
Netherlands Antilles (+599)
Svalbard (+47)
Ascension (+247)
Tristan da Cunha (+290)
Australian Antarctic Territory (+)
Ross Dependency (+)
Peter I Island (+)
Queen Maud Land (+)
British Antarctic Territory (+)
























SEND










Request Discount






Mr
Mrs
Ms
Dr






















Afghanistan (+93)
Albania (+355)
Algeria (+213)
Andorra (+376)
Angola (+244)
Antigua and Barbuda (+-267)
Argentina (+54)
Armenia (+374)
Australia (+61)
Austria (+43)
Azerbaijan (+994)
Bahamas, The (+-241)
Bahrain (+973)
Bangladesh (+880)
Barbados (+-245)
Belarus (+375)
Belgium (+32)
Belize (+501)
Benin (+229)
Bhutan (+975)
Bolivia (+591)
Bosnia and Herzegovina (+387)
Botswana (+267)
Brazil (+55)
Brunei (+673)
Bulgaria (+359)
Burkina Faso (+226)
Burundi (+257)
Cambodia (+855)
Cameroon (+237)
Canada (+1)
Cape Verde (+238)
Central African Republic (+236)
Chad (+235)
Chile (+56)
China, People's Republic of (+86)
Colombia (+57)
Comoros (+269)
Congo, (Congo  Kinshasa) (+243)
Congo, (Congo  Brazzaville) (+242)
Costa Rica (+506)
Cote d'Ivoire (Ivory Coast) (+225)
Croatia (+385)
Cuba (+53)
Cyprus (+357)
Czech Republic (+420)
Denmark (+45)
Djibouti (+253)
Dominica (+-766)
Dominican Republic (++1-809 and 1-829)
Ecuador (+593)
Egypt (+20)
El Salvador (+503)
Equatorial Guinea (+240)
Eritrea (+291)
Estonia (+372)
Ethiopia (+251)
Fiji (+679)
Finland (+358)
France (+33)
Gabon (+241)
Gambia, The (+220)
Georgia (+995)
Germany (+49)
Ghana (+233)
Greece (+30)
Grenada (+-472)
Guatemala (+502)
Guinea (+224)
Guinea-Bissau (+245)
Guyana (+592)
Haiti (+509)
Honduras (+504)
Hungary (+36)
Iceland (+354)
India (+91)
Indonesia (+62)
Iran (+98)
Iraq (+964)
Ireland (+353)
Israel (+972)
Italy (+39)
Jamaica (+-875)
Japan (+81)
Jordan (+962)
Kazakhstan (+7)
Kenya (+254)
Kiribati (+686)
Korea, North (+850)
Korea, South (+82)
Kuwait (+965)
Kyrgyzstan (+996)
Laos (+856)
Latvia (+371)
Lebanon (+961)
Lesotho (+266)
Liberia (+231)
Libya (+218)
Liechtenstein (+423)
Lithuania (+370)
Luxembourg (+352)
Macedonia (+389)
Madagascar (+261)
Malawi (+265)
Malaysia (+60)
Maldives (+960)
Mali (+223)
Malta (+356)
Marshall Islands (+692)
Mauritania (+222)
Mauritius (+230)
Mexico (+52)
Micronesia (+691)
Moldova (+373)
Monaco (+377)
Mongolia (+976)
Montenegro (+382)
Morocco (+212)
Mozambique (+258)
Myanmar (Burma) (+95)
Namibia (+264)
Nauru (+674)
Nepal (+977)
Netherlands (+31)
New Zealand (+64)
Nicaragua (+505)
Niger (+227)
Nigeria (+234)
Norway (+47)
Oman (+968)
Pakistan (+92)
Palau (+680)
Panama (+507)
Papua New Guinea (+675)
Paraguay (+595)
Peru (+51)
Philippines (+63)
Poland (+48)
Portugal (+351)
Qatar (+974)
Romania (+40)
Russia (+7)
Rwanda (+250)
Saint Kitts and Nevis (+-868)
Saint Lucia (+-757)
Saint Vincent and the Grenadines (+-783)
Samoa (+685)
San Marino (+378)
Sao Tome and Principe (+239)
Saudi Arabia (+966)
Senegal (+221)
Serbia (+381)
Seychelles (+248)
Sierra Leone (+232)
Singapore (+65)
Slovakia (+421)
Slovenia (+386)
Solomon Islands (+677)
Somalia (+252)
South Africa (+27)
Spain (+34)
Sri Lanka (+94)
Sudan (+249)
Suriname (+597)
Swaziland (+268)
Sweden (+46)
Switzerland (+41)
Syria (+963)
Tajikistan (+992)
Tanzania (+255)
Thailand (+66)
Timor-Leste (East Timor) (+670)
Togo (+228)
Tonga (+676)
Trinidad and Tobago (+-867)
Tunisia (+216)
Turkey (+90)
Turkmenistan (+993)
Tuvalu (+688)
Uganda (+256)
Ukraine (+380)
United Arab Emirates (+971)
United Kingdom (+44)
United States (+1)
Uruguay (+598)
Uzbekistan (+998)
Vanuatu (+678)
Vatican City (+379)
Venezuela (+58)
Vietnam (+84)
Yemen (+967)
Zambia (+260)
Zimbabwe (+263)
Abkhazia (+995)
China, Republic of (Taiwan) (+886)
Nagorno-Karabakh (+277)
Northern Cyprus (+-302)
Pridnestrovie (Transnistria) (+-160)
Somaliland (+252)
South Ossetia (+995)
Ashmore and Cartier Islands (+)
Christmas Island (+61)
Cocos (Keeling) Islands (+61)
Coral Sea Islands (+)
Heard Island and McDonald Islands (+)
Norfolk Island (+672)
New Caledonia (+687)
French Polynesia (+689)
Mayotte (+262)
Saint Barthelemy (+590)
Saint Martin (+590)
Saint Pierre and Miquelon (+508)
Wallis and Futuna (+681)
French Southern and Antarctic Lands (+)
Clipperton Island (+)
Bouvet Island (+)
Cook Islands (+682)
Niue (+683)
Tokelau (+690)
Guernsey (+44)
Isle of Man (+44)
Jersey (+44)
Anguilla (+-263)
Bermuda (+-440)
British Indian Ocean Territory (+246)
British Sovereign Base Areas (+357)
British Virgin Islands (+-283)
Cayman Islands (+-344)
Falkland Islands (Islas Malvinas) (+500)
Gibraltar (+350)
Montserrat (+-663)
Pitcairn Islands (+)
Saint Helena (+290)
South Georgia & South Sandwich Islands (+)
Turks and Caicos Islands (+-648)
Northern Mariana Islands (+-669)
Puerto Rico (++1-787 and 1-939)
American Samoa (+-683)
Baker Island (+)
Guam (+-670)
Howland Island (+)
Jarvis Island (+)
Johnston Atoll (+)
Kingman Reef (+)
Midway Islands (+)
Navassa Island (+)
Palmyra Atoll (+)
U.S. Virgin Islands (+-339)
Wake Island (+)
Hong Kong (+852)
Macau (+853)
Faroe Islands (+298)
Greenland (+299)
French Guiana (+594)
Guadeloupe (+590)
Martinique (+596)
Reunion (+262)
Aland (+340)
Aruba (+297)
Netherlands Antilles (+599)
Svalbard (+47)
Ascension (+247)
Tristan da Cunha (+290)
Australian Antarctic Territory (+)
Ross Dependency (+)
Peter I Island (+)
Queen Maud Land (+)
British Antarctic Territory (+)
























SEND










Pay by Wire/Invoice






Mr
Mrs
Ms
Dr






























Afghanistan (+93)
Albania (+355)
Algeria (+213)
Andorra (+376)
Angola (+244)
Antigua and Barbuda (+-267)
Argentina (+54)
Armenia (+374)
Australia (+61)
Austria (+43)
Azerbaijan (+994)
Bahamas, The (+-241)
Bahrain (+973)
Bangladesh (+880)
Barbados (+-245)
Belarus (+375)
Belgium (+32)
Belize (+501)
Benin (+229)
Bhutan (+975)
Bolivia (+591)
Bosnia and Herzegovina (+387)
Botswana (+267)
Brazil (+55)
Brunei (+673)
Bulgaria (+359)
Burkina Faso (+226)
Burundi (+257)
Cambodia (+855)
Cameroon (+237)
Canada (+1)
Cape Verde (+238)
Central African Republic (+236)
Chad (+235)
Chile (+56)
China, People's Republic of (+86)
Colombia (+57)
Comoros (+269)
Congo, (Congo  Kinshasa) (+243)
Congo, (Congo  Brazzaville) (+242)
Costa Rica (+506)
Cote d'Ivoire (Ivory Coast) (+225)
Croatia (+385)
Cuba (+53)
Cyprus (+357)
Czech Republic (+420)
Denmark (+45)
Djibouti (+253)
Dominica (+-766)
Dominican Republic (++1-809 and 1-829)
Ecuador (+593)
Egypt (+20)
El Salvador (+503)
Equatorial Guinea (+240)
Eritrea (+291)
Estonia (+372)
Ethiopia (+251)
Fiji (+679)
Finland (+358)
France (+33)
Gabon (+241)
Gambia, The (+220)
Georgia (+995)
Germany (+49)
Ghana (+233)
Greece (+30)
Grenada (+-472)
Guatemala (+502)
Guinea (+224)
Guinea-Bissau (+245)
Guyana (+592)
Haiti (+509)
Honduras (+504)
Hungary (+36)
Iceland (+354)
India (+91)
Indonesia (+62)
Iran (+98)
Iraq (+964)
Ireland (+353)
Israel (+972)
Italy (+39)
Jamaica (+-875)
Japan (+81)
Jordan (+962)
Kazakhstan (+7)
Kenya (+254)
Kiribati (+686)
Korea, North (+850)
Korea, South (+82)
Kuwait (+965)
Kyrgyzstan (+996)
Laos (+856)
Latvia (+371)
Lebanon (+961)
Lesotho (+266)
Liberia (+231)
Libya (+218)
Liechtenstein (+423)
Lithuania (+370)
Luxembourg (+352)
Macedonia (+389)
Madagascar (+261)
Malawi (+265)
Malaysia (+60)
Maldives (+960)
Mali (+223)
Malta (+356)
Marshall Islands (+692)
Mauritania (+222)
Mauritius (+230)
Mexico (+52)
Micronesia (+691)
Moldova (+373)
Monaco (+377)
Mongolia (+976)
Montenegro (+382)
Morocco (+212)
Mozambique (+258)
Myanmar (Burma) (+95)
Namibia (+264)
Nauru (+674)
Nepal (+977)
Netherlands (+31)
New Zealand (+64)
Nicaragua (+505)
Niger (+227)
Nigeria (+234)
Norway (+47)
Oman (+968)
Pakistan (+92)
Palau (+680)
Panama (+507)
Papua New Guinea (+675)
Paraguay (+595)
Peru (+51)
Philippines (+63)
Poland (+48)
Portugal (+351)
Qatar (+974)
Romania (+40)
Russia (+7)
Rwanda (+250)
Saint Kitts and Nevis (+-868)
Saint Lucia (+-757)
Saint Vincent and the Grenadines (+-783)
Samoa (+685)
San Marino (+378)
Sao Tome and Principe (+239)
Saudi Arabia (+966)
Senegal (+221)
Serbia (+381)
Seychelles (+248)
Sierra Leone (+232)
Singapore (+65)
Slovakia (+421)
Slovenia (+386)
Solomon Islands (+677)
Somalia (+252)
South Africa (+27)
Spain (+34)
Sri Lanka (+94)
Sudan (+249)
Suriname (+597)
Swaziland (+268)
Sweden (+46)
Switzerland (+41)
Syria (+963)
Tajikistan (+992)
Tanzania (+255)
Thailand (+66)
Timor-Leste (East Timor) (+670)
Togo (+228)
Tonga (+676)
Trinidad and Tobago (+-867)
Tunisia (+216)
Turkey (+90)
Turkmenistan (+993)
Tuvalu (+688)
Uganda (+256)
Ukraine (+380)
United Arab Emirates (+971)
United Kingdom (+44)
United States (+1)
Uruguay (+598)
Uzbekistan (+998)
Vanuatu (+678)
Vatican City (+379)
Venezuela (+58)
Vietnam (+84)
Yemen (+967)
Zambia (+260)
Zimbabwe (+263)
Abkhazia (+995)
China, Republic of (Taiwan) (+886)
Nagorno-Karabakh (+277)
Northern Cyprus (+-302)
Pridnestrovie (Transnistria) (+-160)
Somaliland (+252)
South Ossetia (+995)
Ashmore and Cartier Islands (+)
Christmas Island (+61)
Cocos (Keeling) Islands (+61)
Coral Sea Islands (+)
Heard Island and McDonald Islands (+)
Norfolk Island (+672)
New Caledonia (+687)
French Polynesia (+689)
Mayotte (+262)
Saint Barthelemy (+590)
Saint Martin (+590)
Saint Pierre and Miquelon (+508)
Wallis and Futuna (+681)
French Southern and Antarctic Lands (+)
Clipperton Island (+)
Bouvet Island (+)
Cook Islands (+682)
Niue (+683)
Tokelau (+690)
Guernsey (+44)
Isle of Man (+44)
Jersey (+44)
Anguilla (+-263)
Bermuda (+-440)
British Indian Ocean Territory (+246)
British Sovereign Base Areas (+357)
British Virgin Islands (+-283)
Cayman Islands (+-344)
Falkland Islands (Islas Malvinas) (+500)
Gibraltar (+350)
Montserrat (+-663)
Pitcairn Islands (+)
Saint Helena (+290)
South Georgia & South Sandwich Islands (+)
Turks and Caicos Islands (+-648)
Northern Mariana Islands (+-669)
Puerto Rico (++1-787 and 1-939)
American Samoa (+-683)
Baker Island (+)
Guam (+-670)
Howland Island (+)
Jarvis Island (+)
Johnston Atoll (+)
Kingman Reef (+)
Midway Islands (+)
Navassa Island (+)
Palmyra Atoll (+)
U.S. Virgin Islands (+-339)
Wake Island (+)
Hong Kong (+852)
Macau (+853)
Faroe Islands (+298)
Greenland (+299)
French Guiana (+594)
Guadeloupe (+590)
Martinique (+596)
Reunion (+262)
Aland (+340)
Aruba (+297)
Netherlands Antilles (+599)
Svalbard (+47)
Ascension (+247)
Tristan da Cunha (+290)
Australian Antarctic Territory (+)
Ross Dependency (+)
Peter I Island (+)
Queen Maud Land (+)
British Antarctic Territory (+)
















Single User Electronic PDF
Site User Electronic PDF
Enterprise Wide Electronic PDF
CD ROM
Hard Copy














SEND










Request Quote






Mr
Mrs
Ms
Dr






























Afghanistan (+93)
Albania (+355)
Algeria (+213)
Andorra (+376)
Angola (+244)
Antigua and Barbuda (+-267)
Argentina (+54)
Armenia (+374)
Australia (+61)
Austria (+43)
Azerbaijan (+994)
Bahamas, The (+-241)
Bahrain (+973)
Bangladesh (+880)
Barbados (+-245)
Belarus (+375)
Belgium (+32)
Belize (+501)
Benin (+229)
Bhutan (+975)
Bolivia (+591)
Bosnia and Herzegovina (+387)
Botswana (+267)
Brazil (+55)
Brunei (+673)
Bulgaria (+359)
Burkina Faso (+226)
Burundi (+257)
Cambodia (+855)
Cameroon (+237)
Canada (+1)
Cape Verde (+238)
Central African Republic (+236)
Chad (+235)
Chile (+56)
China, People's Republic of (+86)
Colombia (+57)
Comoros (+269)
Congo, (Congo  Kinshasa) (+243)
Congo, (Congo  Brazzaville) (+242)
Costa Rica (+506)
Cote d'Ivoire (Ivory Coast) (+225)
Croatia (+385)
Cuba (+53)
Cyprus (+357)
Czech Republic (+420)
Denmark (+45)
Djibouti (+253)
Dominica (+-766)
Dominican Republic (++1-809 and 1-829)
Ecuador (+593)
Egypt (+20)
El Salvador (+503)
Equatorial Guinea (+240)
Eritrea (+291)
Estonia (+372)
Ethiopia (+251)
Fiji (+679)
Finland (+358)
France (+33)
Gabon (+241)
Gambia, The (+220)
Georgia (+995)
Germany (+49)
Ghana (+233)
Greece (+30)
Grenada (+-472)
Guatemala (+502)
Guinea (+224)
Guinea-Bissau (+245)
Guyana (+592)
Haiti (+509)
Honduras (+504)
Hungary (+36)
Iceland (+354)
India (+91)
Indonesia (+62)
Iran (+98)
Iraq (+964)
Ireland (+353)
Israel (+972)
Italy (+39)
Jamaica (+-875)
Japan (+81)
Jordan (+962)
Kazakhstan (+7)
Kenya (+254)
Kiribati (+686)
Korea, North (+850)
Korea, South (+82)
Kuwait (+965)
Kyrgyzstan (+996)
Laos (+856)
Latvia (+371)
Lebanon (+961)
Lesotho (+266)
Liberia (+231)
Libya (+218)
Liechtenstein (+423)
Lithuania (+370)
Luxembourg (+352)
Macedonia (+389)
Madagascar (+261)
Malawi (+265)
Malaysia (+60)
Maldives (+960)
Mali (+223)
Malta (+356)
Marshall Islands (+692)
Mauritania (+222)
Mauritius (+230)
Mexico (+52)
Micronesia (+691)
Moldova (+373)
Monaco (+377)
Mongolia (+976)
Montenegro (+382)
Morocco (+212)
Mozambique (+258)
Myanmar (Burma) (+95)
Namibia (+264)
Nauru (+674)
Nepal (+977)
Netherlands (+31)
New Zealand (+64)
Nicaragua (+505)
Niger (+227)
Nigeria (+234)
Norway (+47)
Oman (+968)
Pakistan (+92)
Palau (+680)
Panama (+507)
Papua New Guinea (+675)
Paraguay (+595)
Peru (+51)
Philippines (+63)
Poland (+48)
Portugal (+351)
Qatar (+974)
Romania (+40)
Russia (+7)
Rwanda (+250)
Saint Kitts and Nevis (+-868)
Saint Lucia (+-757)
Saint Vincent and the Grenadines (+-783)
Samoa (+685)
San Marino (+378)
Sao Tome and Principe (+239)
Saudi Arabia (+966)
Senegal (+221)
Serbia (+381)
Seychelles (+248)
Sierra Leone (+232)
Singapore (+65)
Slovakia (+421)
Slovenia (+386)
Solomon Islands (+677)
Somalia (+252)
South Africa (+27)
Spain (+34)
Sri Lanka (+94)
Sudan (+249)
Suriname (+597)
Swaziland (+268)
Sweden (+46)
Switzerland (+41)
Syria (+963)
Tajikistan (+992)
Tanzania (+255)
Thailand (+66)
Timor-Leste (East Timor) (+670)
Togo (+228)
Tonga (+676)
Trinidad and Tobago (+-867)
Tunisia (+216)
Turkey (+90)
Turkmenistan (+993)
Tuvalu (+688)
Uganda (+256)
Ukraine (+380)
United Arab Emirates (+971)
United Kingdom (+44)
United States (+1)
Uruguay (+598)
Uzbekistan (+998)
Vanuatu (+678)
Vatican City (+379)
Venezuela (+58)
Vietnam (+84)
Yemen (+967)
Zambia (+260)
Zimbabwe (+263)
Abkhazia (+995)
China, Republic of (Taiwan) (+886)
Nagorno-Karabakh (+277)
Northern Cyprus (+-302)
Pridnestrovie (Transnistria) (+-160)
Somaliland (+252)
South Ossetia (+995)
Ashmore and Cartier Islands (+)
Christmas Island (+61)
Cocos (Keeling) Islands (+61)
Coral Sea Islands (+)
Heard Island and McDonald Islands (+)
Norfolk Island (+672)
New Caledonia (+687)
French Polynesia (+689)
Mayotte (+262)
Saint Barthelemy (+590)
Saint Martin (+590)
Saint Pierre and Miquelon (+508)
Wallis and Futuna (+681)
French Southern and Antarctic Lands (+)
Clipperton Island (+)
Bouvet Island (+)
Cook Islands (+682)
Niue (+683)
Tokelau (+690)
Guernsey (+44)
Isle of Man (+44)
Jersey (+44)
Anguilla (+-263)
Bermuda (+-440)
British Indian Ocean Territory (+246)
British Sovereign Base Areas (+357)
British Virgin Islands (+-283)
Cayman Islands (+-344)
Falkland Islands (Islas Malvinas) (+500)
Gibraltar (+350)
Montserrat (+-663)
Pitcairn Islands (+)
Saint Helena (+290)
South Georgia & South Sandwich Islands (+)
Turks and Caicos Islands (+-648)
Northern Mariana Islands (+-669)
Puerto Rico (++1-787 and 1-939)
American Samoa (+-683)
Baker Island (+)
Guam (+-670)
Howland Island (+)
Jarvis Island (+)
Johnston Atoll (+)
Kingman Reef (+)
Midway Islands (+)
Navassa Island (+)
Palmyra Atoll (+)
U.S. Virgin Islands (+-339)
Wake Island (+)
Hong Kong (+852)
Macau (+853)
Faroe Islands (+298)
Greenland (+299)
French Guiana (+594)
Guadeloupe (+590)
Martinique (+596)
Reunion (+262)
Aland (+340)
Aruba (+297)
Netherlands Antilles (+599)
Svalbard (+47)
Ascension (+247)
Tristan da Cunha (+290)
Australian Antarctic Territory (+)
Ross Dependency (+)
Peter I Island (+)
Queen Maud Land (+)
British Antarctic Territory (+)
























SEND









Market Reports Center © Copyright 2017 All rights reserved.




























































SignPath Pharma Inc - Product Pipeline Review - 2015

















































































ABOUT US
BLOG
CONTACT US
FAQ























USD
EUR
GBP



USD 
▼

USD
EUR
GBP






€
EUR
$
USD
£
GBP







+353-1-416-8900REST OF WORLD



1-800-526-8630U.S. (TOLL FREE)








 




Advanced








Price From: 
€1334EUR$1,500USD£1,192GBP 
View Pricing




You are here:


Home
>






Categories
>






Company Reports











 
SELECT A FORMAT








€1334EUR$1,500USD£1,192GBP



                                                        Single User
                                                         Electronic (PDF)






                                                                            
                                                                            This is a single user license, allowing one specific user access to the product. The report will be emailed to you.  The report is sent in PDF format. 

                                                










€2668EUR$3,000USD£2,384GBP



                                                        Site License
                                                         Electronic (PDF)






                                                                            
                                                                            This is a site license, allowing all users within a given geographical location of your organisation access to the product. The report will be emailed to you.  The report is sent in PDF format. 

                                                










€4001EUR$4,500USD£3,576GBP



                                                        Enterprisewide
                                                         Electronic (PDF)






                                                                            
                                                                            This is an enterprise license, allowing all employees within your organisation access to the product. The report will be emailed to you.  The report is sent in PDF format. 

                                                







  ADD TO BASKET




                                                                        order by fax
                                        

                                            need a quote ?
                                        



 

OUR CLIENTS












HAVE A QUESTION?
EMAIL US
VIEW FAQs



RECENTLY VIEWED PRODUCTS











Partner of Research and MarketsVACCINATING 40,000 CHILDREN IN 2017





WHY CHOOSE RESEARCH AND MARKETS?



WORLD'S LARGEST SELECTION




TRUSTED BY THE BEST




CUSTOMER FOCUSED




SAFE & SECURE







I appreciate your quick and amazing responses. Your assistance has been really helpful for me in making

                         business decisions. Thank you very much!
                        
                    



                            READ MORE
                        


Willliam Wu
Marketing Manager
Leedarson Lighting















SignPath Pharma Inc - Product Pipeline Review - 2015



ID: 3345070
Company Profile
July 2015
27 pages

Global Markets Direct                            











DESCRIPTION


TABLE OF CONTENTS


SAMPLES


FORMATS







1 of 4











                            LOGIN TO ACCESS EXECUTIVE SUMMARY
                        



                            PRINTER FRIENDLY
                        



                            PRINTABLE PDF BROCHURE
                        

SEND TO A FRIEND






                                                                                    SignPath Pharma Inc - Product Pipeline Review - 2015Summarythe, ‘SignPath Pharma Inc - Product Pipeline Review - 2015’, provides an overview of the SignPath Pharma Inc’s pharmaceutical research and development focus.This report provides comprehensive information on the current therapeutic developmental pipeline of SignPath Pharma Inc’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.the report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from the proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by the team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- The report provides brief overview of SignPath Pharma Inc including business description, key information and facts, and its locations and subsidiaries- The report reviews current pipeline of SignPath Pharma Inc’s human therapeutic division and enlists all their major and minor projects- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones- Special feature on out-licensed and partnered product portfolio- The report summarizes all the dormant and discontinued pipeline projects- Latest company statement- Latest news and deals relating to the SignPath Pharma Inc’s pipeline productsReasons to buy- Evaluate SignPath Pharma Inc’s strategic position with total access to detailed information on its product pipeline- Assess the growth potential of SignPath Pharma Inc in its therapy areas of focus- Identify new drug targets and therapeutic classes in the SignPath Pharma Inc’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps- Develop strategic initiatives by understanding the focus areas of SignPath Pharma Inc and exploit collaboration and partnership opportunities- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage- Plan mergers and acquisitions effectively by identifying the most promising pipeline of SignPath Pharma Inc- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope- Explore the dormant and discontinued projects of SignPath Pharma Inc and identify potential opportunities in those areas- Avoid Intellectual Property Rights related issues
                                                                                

 SHOW LESS
                                                                                

 READ MORE
                                                                                



Note: Product cover images may vary from those shown




2 of 4







                            LOGIN TO ACCESS EXECUTIVE SUMMARY
                        



                            PRINTER FRIENDLY
                        



                            PRINTABLE PDF BROCHURE
                        

SEND TO A FRIEND






                                                                    List of TablesList of FiguresSignPath Pharma Inc SnapshotSignPath Pharma Inc OverviewKey InformationKey FactsSignPath Pharma Inc - Research and Development OverviewKey Therapeutic AreasSignPath Pharma Inc - Pipeline ReviewPipeline Products by Stage of DevelopmentPipeline Products - MonotherapySignPath Pharma Inc - Pipeline Products GlanceSignPath Pharma Inc - Clinical Stage Pipeline ProductsPhase I Products/Combination Treatment ModalitiesSignPath Pharma Inc - Early Stage Pipeline ProductsIND/CTA Filed Products/Combination Treatment ModalitiesPreclinical Products/Combination Treatment ModalitiesSignPath Pharma Inc - Drug ProfilesLiposomal CurcuminProduct DescriptionMechanism of ActionR&D ProgressEU-8120Product DescriptionMechanism of ActionR&D ProgressLiposomal PLGA CurcuminProduct DescriptionMechanism of ActionR&D ProgressNanocurcuminProduct DescriptionMechanism of ActionR&D ProgressSignPath Pharma Inc - Pipeline AnalysisSignPath Pharma Inc - Pipeline Products by TargetSignPath Pharma Inc - Pipeline Products by Route of AdministrationSignPath Pharma Inc - Pipeline Products by Molecule TypeSignPath Pharma Inc - Pipeline Products by Mechanism of ActionSignPath Pharma Inc - Recent Pipeline UpdatesSignPath Pharma Inc - Dormant ProjectsSignPath Pharma Inc - Locations And SubsidiariesHead OfficeAppendixMethodologyCoverageSecondary ResearchPrimary ResearchExpert Panel ValidationContact UsDisclaimer   List of TablesSignPath Pharma Inc, Key InformationSignPath Pharma Inc, Key FactsSignPath Pharma Inc - Pipeline by Indication, 2015SignPath Pharma Inc - Pipeline by Stage of Development, 2015SignPath Pharma Inc - Monotherapy Products in Pipeline, 2015SignPath Pharma Inc - Phase I, 2015SignPath Pharma Inc - IND/CTA Filed, 2015SignPath Pharma Inc - Preclinical, 2015SignPath Pharma Inc - Pipeline by Target, 2015SignPath Pharma Inc - Pipeline by Route of Administration, 2015SignPath Pharma Inc - Pipeline by Molecule Type, 2015SignPath Pharma Inc - Pipeline Products by Mechanism of Action, 2015SignPath Pharma Inc - Recent Pipeline Updates, 2015SignPath Pharma Inc - Dormant Developmental Projects,2015   List of FiguresSignPath Pharma Inc - Pipeline by Top 10 Indication, 2015SignPath Pharma Inc - Pipeline by Stage of Development, 2015SignPath Pharma Inc - Monotherapy Products in Pipeline, 2015SignPath Pharma Inc - Pipeline by Top 10 Route of Administration, 2015SignPath Pharma Inc - Pipeline by Top 10 Molecule Type, 2015
                                                                
Note: Product cover images may vary from those shown




3 of 4





LOADING...







4 of 4






Note: Product cover images may vary from those shown








RELATED PRODUCTS 







UMN Pharma Inc. - Product Pipeline Review - 2015


 Company Profile
August 2015




FROM


€1334EUR$1,500USD£1,192GBP







Antares Pharma, Inc. - Product Pipeline Review - 2015


 Company Profile
29 Pages
May 2015
Region: Global




FROM


€1334EUR$1,500USD£1,192GBP







Array BioPharma Inc. - Product Pipeline Review - 2015


 Company Profile
November 2015




FROM


€1334EUR$1,500USD£1,192GBP







PLx Pharma Inc. - Product Pipeline Review - 2015


 Company Profile
May 2015




FROM


€1334EUR$1,500USD£1,192GBP







Beta Pharma, Inc. - Product Pipeline Review - 2015


 Company Profile
February 2015




FROM


€1334EUR$1,500USD£1,192GBP







MEI Pharma, Inc. - Product Pipeline Review - 2015


 Company Profile
November 2015




FROM


€1334EUR$1,500USD£1,192GBP







Cerulean Pharma, Inc. - Product Pipeline Review - 2015


 Company Profile
August 2015




FROM


€1334EUR$1,500USD£1,192GBP







Acceleron Pharma, Inc. - Product Pipeline Review - 2016


 Company Profile
April 2016




FROM


€1334EUR$1,500USD£1,192GBP







Advicenne Pharma - Product Pipeline Review - 2015


 Company Profile
August 2015




FROM


€1334EUR$1,500USD£1,192GBP







OBI Pharma, Inc. - Product Pipeline Review - 2015


 Company Profile
November 2015




FROM


€1334EUR$1,500USD£1,192GBP








 close

SignPath Pharma Inc - Product Pipeline Review - 2015



 close

ASK A QUESTION

*Required Information
 
Product: SignPath Pharma Inc - Product Pipeline Review - 2015


YOUR QUESTION*







YOUR CONTACT DETAILS*

Title
Mr
Mrs
Dr
Miss
Ms
Prof




First Name




Last Name




Email Address




Country
Please Select
------------------------------
United States
United Kingdom
Germany
Canada
Australia
------------------------------
Afghanistan
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica-Casey
Antarctica-Scott
Antigua and Barbuda
Argentina
Armenia
Aruba
Ascension Island
Ashmore and Cartier Islands
Atlantic East
Atlantic West
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia and Herzegovina
Botswana
Brazil
British Virgin Islands
Brunei
Bulgaria
Burkina Faso
Burma
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Clipperton Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo
Cook Islands
Costa Rica
Croatia
Cuba
Curaco 
Cyprus
Czech Republic
Democratic Republic of Congo
Denmark
Djibouti
Dominica
Dominican Republic
East Timor
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands (Islas Malvinas)
Faroe Islands
Fiji Islands
Finland
France
French Guiana
French Polynesia
Gabon
Gambia
Gaza Strip
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guinea
Guinea-Bissau
Guyana
Haiti
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran
Iraq
Ireland
Israel
Italy
Ivory Coast
Ivory Coast (Cote d'Ivoire)
Jamaica
Japan
Jordan
Kazakhstan
Kenya
Kiribati
Kosovo
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macau
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte Islands
Mexico
Micronesia
Moldova
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
Netherlands Antilles
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Islands
North Korea
Northern Ireland
Northern Marianas
Norway
Oman
Pakistan
Palau
Palestine
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Poland
Portugal
Puerto Rico
Qatar
Reunion
Romania
Russia
Rwanda
Saint Christopher Nevis
Saint Helena
Saint Kitts and Nevis
Saint Lucia
Saint Martin
Saint Vincent and the Grenadines
Samoa
San Marino
Sao Tome
Saudi Arabia
Scotland
Senegal
Serbia
Serbia and Montenegro
Seychelles
Sierra Leone
Singapore
Sint Maarten
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Korea
Spain
Sri Lanka
Sudan
Suriname
Swaziland
Sweden
Switzerland
Syria
Tahiti
Taiwan
Tajikistan
Tanzania
Thailand
Togo
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
Uruguay
Uzbekistan
Vanuatu
Vatican City (Holy See)
Venezuela
Vietnam
Virgin Islands
Wallis And Futuna
West Bank
West Indies
Western Sahara
Yemen
Yugoslavia
Zaire
Zambia
Zimbabwe




Phone Number



+1
+11
+1-242
+1-246
+1-264
+1-268
+1-284
+1-345
+1-441
+1-473
+1-649
+1-664
+1-670
+1-671
+1-684
+1-758
+1-767
+1-784
+1-787
+1-809
+1-868
+1-869
+1-876
+20
+212
+213
+216
+218
+220
+221
+222
+224
+225
+226
+227
+228
+229
+23
+230
+231
+232
+233
+234
+235
+236
+237
+238
+239
+240
+241
+242
+243
+244
+245
+247
+248
+249
+250
+251
+252
+253
+254
+255
+256
+257
+258
+260
+261
+263
+264
+265
+266
+267
+268
+269
+27
+284
+290
+291
+297
+298
+299
+30
+31
+32
+33
+34
+350
+351
+352
+353
+354
+355
+356
+357
+358
+359
+36
+370
+371
+372
+373
+374
+375
+376
+377
+378
+379
+380
+381
+382
+385
+386
+387
+389
+39
+40
+41
+420
+421
+423
+43
+44
+45
+46
+47
+48
+49
+500
+501
+502
+503
+504
+505
+506
+507
+509
+51
+52
+53
+54
+55
+56
+57
+58
+590
+591
+592
+593
+594
+595
+596
+597
+598
+599
+60
+61
+6101
+62
+63
+64
+65
+66
+670
+672
+673
+674
+675
+677
+678
+679
+680
+681
+682
+683
+685
+686
+687
+688
+689
+691
+692
+7
+81
+82
+84
+850
+852
+853
+855
+856
+86
+869
+871
+874
+880
+886
+90
+91
+92
+93
+94
+95
+960
+961
+962
+963
+964
+965
+966
+967
+968
+970
+971
+972
+973
+974
+975
+976
+977
+98
+992
+993
+994
+995
+996
+998












We request your telephone number so we can contact you in the event we have difficulty reaching you via email.
                    We aim to respond to all questions on the same business day.





 



 close

SEND TO A FRIEND

* Required Information
 FRIEND'S DETAILS

Full Name*




Email Address*




Message to friend




YOUR CONTACT DETAILS

Full Name*




Email Address*













 


 close

Request a Quote

 
Please complete the below form and click "send request" to obtain a pdf quotation and order form.
This document will be available for immediate download and will also be emailed to you.
            
* Required Information


YOUR ADDRESS

Address 1*




Address 2




Address 3




City*




Postal/ZIP Code




Country*
Please Select
------------------------------
United States
United Kingdom
Germany
Canada
Australia
------------------------------
Afghanistan
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica-Casey
Antarctica-Scott
Antigua and Barbuda
Argentina
Armenia
Aruba
Ascension Island
Ashmore and Cartier Islands
Atlantic East
Atlantic West
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia and Herzegovina
Botswana
Brazil
British Virgin Islands
Brunei
Bulgaria
Burkina Faso
Burma
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Clipperton Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo
Cook Islands
Costa Rica
Croatia
Cuba
Curaco 
Cyprus
Czech Republic
Democratic Republic of Congo
Denmark
Djibouti
Dominica
Dominican Republic
East Timor
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands (Islas Malvinas)
Faroe Islands
Fiji Islands
Finland
France
French Guiana
French Polynesia
Gabon
Gambia
Gaza Strip
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guinea
Guinea-Bissau
Guyana
Haiti
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran
Iraq
Ireland
Israel
Italy
Ivory Coast
Ivory Coast (Cote d'Ivoire)
Jamaica
Japan
Jordan
Kazakhstan
Kenya
Kiribati
Kosovo
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macau
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte Islands
Mexico
Micronesia
Moldova
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
Netherlands Antilles
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Islands
North Korea
Northern Ireland
Northern Marianas
Norway
Oman
Pakistan
Palau
Palestine
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Poland
Portugal
Puerto Rico
Qatar
Reunion
Romania
Russia
Rwanda
Saint Christopher Nevis
Saint Helena
Saint Kitts and Nevis
Saint Lucia
Saint Martin
Saint Vincent and the Grenadines
Samoa
San Marino
Sao Tome
Saudi Arabia
Scotland
Senegal
Serbia
Serbia and Montenegro
Seychelles
Sierra Leone
Singapore
Sint Maarten
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Korea
Spain
Sri Lanka
Sudan
Suriname
Swaziland
Sweden
Switzerland
Syria
Tahiti
Taiwan
Tajikistan
Tanzania
Thailand
Togo
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
Uruguay
Uzbekistan
Vanuatu
Vatican City (Holy See)
Venezuela
Vietnam
Virgin Islands
Wallis And Futuna
West Bank
West Indies
Western Sahara
Yemen
Yugoslavia
Zaire
Zambia
Zimbabwe




State





YOUR DETAILS

Title*
Mr
Mrs
Dr
Miss
Ms
Prof




First Name*




Last Name*




Organisation*




Email Address*




Phone Number*



+1
+11
+1-242
+1-246
+1-264
+1-268
+1-284
+1-345
+1-441
+1-473
+1-649
+1-664
+1-670
+1-671
+1-684
+1-758
+1-767
+1-784
+1-787
+1-809
+1-868
+1-869
+1-876
+20
+212
+213
+216
+218
+220
+221
+222
+224
+225
+226
+227
+228
+229
+23
+230
+231
+232
+233
+234
+235
+236
+237
+238
+239
+240
+241
+242
+243
+244
+245
+247
+248
+249
+250
+251
+252
+253
+254
+255
+256
+257
+258
+260
+261
+263
+264
+265
+266
+267
+268
+269
+27
+284
+290
+291
+297
+298
+299
+30
+31
+32
+33
+34
+350
+351
+352
+353
+354
+355
+356
+357
+358
+359
+36
+370
+371
+372
+373
+374
+375
+376
+377
+378
+379
+380
+381
+382
+385
+386
+387
+389
+39
+40
+41
+420
+421
+423
+43
+44
+45
+46
+47
+48
+49
+500
+501
+502
+503
+504
+505
+506
+507
+509
+51
+52
+53
+54
+55
+56
+57
+58
+590
+591
+592
+593
+594
+595
+596
+597
+598
+599
+60
+61
+6101
+62
+63
+64
+65
+66
+670
+672
+673
+674
+675
+677
+678
+679
+680
+681
+682
+683
+685
+686
+687
+688
+689
+691
+692
+7
+81
+82
+84
+850
+852
+853
+855
+856
+86
+869
+871
+874
+880
+886
+90
+91
+92
+93
+94
+95
+960
+961
+962
+963
+964
+965
+966
+967
+968
+970
+971
+972
+973
+974
+975
+976
+977
+98
+992
+993
+994
+995
+996
+998











                                PO Number
                                (if applicable)







PRODUCT FORMAT




License
Format
Properties
Price




 
SINGLE USER Electronic (PDF)                                                



                                            The report will be emailed to you.  The report is sent in PDF format. 
                                        

                                            This is a single user license, allowing one specific user access to the product.
                                        

€1334EUR$1,500USD£1,192GBP





 
SITE LICENSE Electronic (PDF)                                                



                                            The report will be emailed to you.  The report is sent in PDF format. 
                                        

                                            This is a site license, allowing all users within a given geographical location of your organisation access to the product.
                                        

€2668EUR$3,000USD£2,384GBP





 
ENTERPRISEWIDE Electronic (PDF)                                                



                                            The report will be emailed to you.  The report is sent in PDF format. 
                                        

                                            This is an enterprise license, allowing all employees within your organisation access to the product.
                                        

€4001EUR$4,500USD£3,576GBP







* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.





 





























SignPath Pharma Inc - Product Pipeline Review - 2014























































  info@wiseguyreports.com  |   
 Chat with us   |    +1 (339) 368 6938 (US)  |     +44 208 133 9349 (UK) 



 Login    Register 






















Home


Report Categories







Premium Reports

Access to 600000+ Premium Reports











  
                                Aerospace & Defense
                              









  
                                Agri & Food
                              









  
                                Automotive
                              









  
                                Basic Materials
                              











  
                                Consumer Goods & Retail
                              









  
                                Energy
                              









  
                                Life Sciences
                              









  
                                Manufacturing & Construction
                              











  
                                Services
                              









  
                                Telecom & IT
                              









  
                                Education
                              









  
                                Security & Intelligence Systems
                              











  
                                Technology
                              









  
                                Company Reports
                              










Report Categories 










Aerospace & Defense
                





Agri & Food
                





Automotive
                





Basic Materials
                







Consumer Goods & Retail
                





Energy
                





Life Sciences
                





Manufacturing & Construction
                







Services
                





Telecom & IT
                





Education
                





Security & Intelligence Systems
                







Technology
                





Company Reports
                








Publisher
Knowledgestore

Countries 
              


Browse by Country
Browse by Continent
Browse by Group / Region



 Conferences
              


Upcoming Conferences
Seminars




 Conferences
              


Upcoming Conferences
Seminars




Countries 

Browse by Country
Browse by Continent
Browse by Group / Region



News & Blog

 Press Release
Blog



News & Blogs

 Press Release
Blogs


FAQs

About Us

About Our Company
Our Team
Life At WGR


Careers
Contact Us











                                         There are no items currently in your basket.
                                     













There are no items currently in your basket!














  




































Search 
                






 














Home
All Reports
SignPath Pharma Inc - Product Pipeline Review - 2014









 


  SignPath Pharma Inc - Product Pipeline Review - 2014


WGR11148
30 
                  June, 2014 
Global
22 pages 
Global Markets Direct






















Description




Table of Content




Sample Report




Enquiry before buy




Related Reports





SignPath Pharma Inc - Product Pipeline Review - 2014SummaryGlobal Markets Direct’s, ‘SignPath Pharma Inc - Product Pipeline Review - 2014’, provides an overview of the SignPath Pharma Inc’s pharmaceutical research and development focus.This report provides comprehensive information on the current therapeutic developmental pipeline of SignPath Pharma Inc’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- The report provides brief overview of SignPath Pharma Inc including business description, key information and facts, and its locations and subsidiaries- The report reviews current pipeline of SignPath Pharma Inc’s human therapeutic division and enlists all their major and minor projects- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones - Special feature on out-licensed and partnered product portfolio- The report summarizes all the dormant and discontinued pipeline projects- Latest company statement - Latest news and deals relating to the SignPath Pharma Inc’s pipeline productsReasons to buy- Evaluate SignPath Pharma Inc’s strategic position with total access to detailed information on its product pipeline- Assess the growth potential of SignPath Pharma Inc in its therapy areas of focus- Identify new drug targets and therapeutic classes in the SignPath Pharma Inc’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps- Develop strategic initiatives by understanding the focus areas of SignPath Pharma Inc and exploit collaboration and partnership opportunities- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage- Plan mergers and acquisitions effectively by identifying the most promising pipeline of SignPath Pharma Inc- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope- Explore the dormant and discontinued projects of SignPath Pharma Inc and identify potential opportunities in those areas- Avoid Intellectual Property Rights related issues


Table of ContentsTable of Contents 2List of Tables 3List of Figures 3SignPath Pharma Inc Snapshot 4SignPath Pharma Inc Overview 4Key Information 4Key Facts 4SignPath Pharma Inc - Research and Development Overview 5Key Therapeutic Areas 5SignPath Pharma Inc - Pipeline Review 7Pipeline Products by Stage of Development 7Pipeline Products - Monotherapy 8SignPath Pharma Inc - Pipeline Products Glance 9SignPath Pharma Inc - Clinical Stage Pipeline Products 9Phase I Products/Combination Treatment Modalities 9SignPath Pharma Inc - Early Stage Pipeline Products 10Preclinical Products/Combination Treatment Modalities 10Discovery Products/Combination Treatment Modalities 11SignPath Pharma Inc - Drug Profiles 12Liposomal Curcumin 12Product Description 12Mechanism of Action 12R&D Progress 12PLGA Liposomal Curcumin 14Product Description 14Mechanism of Action 14R&D Progress 14Polymeric Nanocurcumin 15Product Description 15Mechanism of Action 15R&D Progress 15SignPath Pharma Inc - Pipeline Analysis 17SignPath Pharma Inc - Pipeline Products by Route of Administration 17SignPath Pharma Inc - Pipeline Products by Molecule Type 18SignPath Pharma Inc - Recent Pipeline Updates 19SignPath Pharma Inc - Locations And Subsidiaries 20Head Office 20Appendix 21Methodology 21Coverage 21Secondary Research 21Primary Research 21Expert Panel Validation 21Contact Us 22Disclaimer 22List of TablesSignPath Pharma Inc, Key Information 4SignPath Pharma Inc, Key Facts 4SignPath Pharma Inc - Pipeline by Indication, 2014 6SignPath Pharma Inc - Pipeline by Stage of Development, 2014 7SignPath Pharma Inc - Monotherapy Products in Pipeline, 2014 8SignPath Pharma Inc - Phase I, 2014 9SignPath Pharma Inc - Preclinical, 2014 10SignPath Pharma Inc - Discovery, 2014 11SignPath Pharma Inc - Pipeline by Route of Administration, 2014 17SignPath Pharma Inc - Pipeline by Molecule Type, 2014 18SignPath Pharma Inc - Recent Pipeline Updates, 2014 19List of FiguresSignPath Pharma Inc - Pipeline by Top 10 Indication, 2014 6SignPath Pharma Inc - Pipeline by Stage of Development, 2014 7SignPath Pharma Inc - Monotherapy Products in Pipeline, 2014 8SignPath Pharma Inc - Pipeline by Top 10 Route of Administration, 2014 17SignPath Pharma Inc - Pipeline by Top 10 Molecule Type, 2014 18







                                Request a Sample Report
                                




Name:*










Email:*


(Optional: Request you to please fill in your Corporate Email-ID)



Job Title:*





Company:*





Phone No:*





Your Country:*

--select country--
Afghanistan
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antigua & Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia & Herzegovina
Botswana
Brazil
Brunei
Bulgaria
Burkina Faso
Burundi
Cambodja
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Colombia
Comoros
Congo-Brazzaville
Congo-Kinshasa
Cook Islands
Costa Rica
Cote d"Ivoire
Croatia
Cuba
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland (Malvinas)
Faroes
Fiji
Finland
France
French-Guiana
Tahiti(French Polinesia)
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guinea
Guinea-Bissau
Guyana
Haiti
Vatican City
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran
Iraq
Ireland
Israel
Italy
Jamaica
Japan
Jordan
Kazakhstan
Kenya
Kiribati
North Korea
South Korea
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macao
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mexico
Micronesia
Moldova
Monaco
Mongolia
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
Netherlands Antilles
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Norfolk
Northern Mariana
Norway
Oman
Pakistan
Palau
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Reunion
Romania
Russian Federation
Rwanda
Saint Helena
Saint Lucia
Saint Pierre and Miquelon
St Vincent & the Grenadines
Samoa
San Marino
Sao Tome & Principe
Saudi Arabia
Senegal
Seychelles
Sierra Leone
Singapore
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syria
Taiwan
Tajikistan
Tanzania
Thailand
Togo
Tokelau
Tonga
Trinidad & Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States of America
Uruguay
Uzbekistan
Vanuatu
Venezuela
Viet Nam
Virgin Islands British
Virgin Islands US
Wales
Western Sahara
Yemen
Zambia
Zimbabwe
Timor-Leste
Curacao
St Kitts & Nevis
Sint Maarten
Guernsey
Isle of Man
Jersey
Niue
Montenegro



Do you have any Specific field of Interest?*

















Confirm


 








Make an enquiry before buying this Report




Name:*










Email:*


(Optional: Request you to please fill in your Corporate Email-ID)



Job Title:*





Company:*





Phone No:*





Your Country:*

--select country--
Afghanistan
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antigua & Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia & Herzegovina
Botswana
Brazil
Brunei
Bulgaria
Burkina Faso
Burundi
Cambodja
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Colombia
Comoros
Congo-Brazzaville
Congo-Kinshasa
Cook Islands
Costa Rica
Cote d"Ivoire
Croatia
Cuba
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland (Malvinas)
Faroes
Fiji
Finland
France
French-Guiana
Tahiti(French Polinesia)
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guinea
Guinea-Bissau
Guyana
Haiti
Vatican City
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran
Iraq
Ireland
Israel
Italy
Jamaica
Japan
Jordan
Kazakhstan
Kenya
Kiribati
North Korea
South Korea
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macao
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mexico
Micronesia
Moldova
Monaco
Mongolia
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
Netherlands Antilles
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Norfolk
Northern Mariana
Norway
Oman
Pakistan
Palau
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Reunion
Romania
Russian Federation
Rwanda
Saint Helena
Saint Lucia
Saint Pierre and Miquelon
St Vincent & the Grenadines
Samoa
San Marino
Sao Tome & Principe
Saudi Arabia
Senegal
Seychelles
Sierra Leone
Singapore
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syria
Taiwan
Tajikistan
Tanzania
Thailand
Togo
Tokelau
Tonga
Trinidad & Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States of America
Uruguay
Uzbekistan
Vanuatu
Venezuela
Viet Nam
Virgin Islands British
Virgin Islands US
Wales
Western Sahara
Yemen
Zambia
Zimbabwe
Timor-Leste
Curacao
St Kitts & Nevis
Sint Maarten
Guernsey
Isle of Man
Jersey
Niue
Montenegro



Your Enquiry*

















Confirm


 
















Purchase this Market Research Report







 USD




 GBP




 EURO




 YEN




 INR







                        1-user PDF
                         
                          $1,500.00
                        

 
                        Site PDF 
                         
                          $3,000.00
                        

 
                        Enterprise PDF 
                         
                          $4,500.00
                        





  1-user PDF
  
 
    1,141.20
   

 
  Site PDF 
  
 
  2,282.40
  

 
  Enterprise PDF 
  
 
  3,423.60
  





  1-user PDF
  
 
    1,275.60
   

 
  Site PDF 
  
 
  2,551.20
  

 
  Enterprise PDF 
  
 
  3,826.80
  





  1-user PDF
  
 
    165,867.00
   

 
  Site PDF 
  
 
  331,734.00
  

 
  Enterprise PDF 
  
 
  497,601.00
  





  1-user PDF
  
 
    96,206.85
   

 
  Site PDF 
  
 
  192,413.70
  

 
  Enterprise PDF 
  
 
  288,620.55
  









Add To Cart
BUY NOW





 















  Email Report


  Sample Report




  Save Page


  Any Questions




  Download information


  Check Discount




  Download Order Form









  Email Report


  Sample Report




  Save Page


  Any Questions




  Download information


  Check Discount




  Download Order Form






Contact Us










Akash Anand
Domain Head Business Development
sales@wiseguyreports.com
+1 (646) 843 9312 (US)
+44 208 133 9349 (UK)













Rishabh Arora
Domain Head Business Development
sales@wiseguyreports.com
+44-208-133-9346













Abu Koshy
Domain Head Business Development
sales@wiseguyreports.com
+1 339 368 6938










Related Reports








                  ×
              
Tell a friend about this report 




Your Name:*





Your Email:*





Friend's Name:*





Friend's Email:*





Your Enquiry*









Send


 



































SignPath Pharma Inc - Product Pipeline Review - 2014 - RnR Market Research












































Advanced search


1 888 391 5441

sales@rnrmarketresearch.com


Search Market Research Reports






 
 
﻿  Market Research Assistance+ 1-888-391-5441sales@rnrmarketresearch.com

On the Web       

Related Markets
BiotechnologyBiomaterialsBiomarkersStem CellDrug DiscoveryIndustrial BiotechnologyWound CareEnzymeMicroarrayBiopharmaceuticalCell Culture
Related Market ReportsSignPath Pharma Inc - Product Pipeline Review - 2015



Home  
 > Life Sciences > Pharmaceuticals > Report Detail


 

SignPath Pharma Inc - Product Pipeline Review - 2014


Publisher Name :
Global Markets Direct
 Date: 30-Jun-2014
No. of pages: 22







Price:

Single User License: US $1500
Corporate User License: US $4500






 
Report DescriptionTable of ContentNews & BlogOther ReportsOur Offerings




Global Markets Direct's, SignPath Pharma Inc Product Pipeline Review 2014', provides an overview of the SignPath Pharma Inc's pharmaceutical research and development focus.
This report provides comprehensive information on the current therapeutic developmental pipeline of SignPath Pharma Inc's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.
Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope

The report provides brief overview of SignPath Pharma Inc including business description, key information and facts, and its locations and subsidiaries
The report reviews current pipeline of SignPath Pharma Inc's human therapeutic division and enlists all their major and minor projects
The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
Special feature on out-licensed and partnered product portfolio
The report summarizes all the dormant and discontinued pipeline projects
Latest company statement
Latest news and deals relating to the SignPath Pharma Inc's pipeline products

Reasons to buy

Evaluate SignPath Pharma Inc's strategic position with total access to detailed information on its product pipeline
Assess the growth potential of SignPath Pharma Inc in its therapy areas of focus
Identify new drug targets and therapeutic classes in the SignPath Pharma Inc's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
Develop strategic initiatives by understanding the focus areas of SignPath Pharma Inc and exploit collaboration and partnership opportunities
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Plan mergers and acquisitions effectively by identifying the most promising pipeline of SignPath Pharma Inc
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Explore the dormant and discontinued projects of SignPath Pharma Inc and identify potential opportunities in those areas
Avoid Intellectual Property Rights related issues



SignPath Pharma Inc - Product Pipeline Review - 2014
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
SignPath Pharma Inc Snapshot 4
SignPath Pharma Inc Overview 4
Key Information 4
Key Facts 4
SignPath Pharma Inc - Research and Development Overview 5
Key Therapeutic Areas 5
SignPath Pharma Inc - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
SignPath Pharma Inc - Pipeline Products Glance 9
SignPath Pharma Inc - Clinical Stage Pipeline Products 9
Phase I Products/Combination Treatment Modalities 9
SignPath Pharma Inc - Early Stage Pipeline Products 10
Preclinical Products/Combination Treatment Modalities 10
Discovery Products/Combination Treatment Modalities 11
SignPath Pharma Inc - Drug Profiles 12
Liposomal Curcumin 12
Product Description 12
Mechanism of Action 12
R&D Progress 12
PLGA Liposomal Curcumin 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
Polymeric Nanocurcumin 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
SignPath Pharma Inc - Pipeline Analysis 17
SignPath Pharma Inc - Pipeline Products by Route of Administration 17
SignPath Pharma Inc - Pipeline Products by Molecule Type 18
SignPath Pharma Inc - Recent Pipeline Updates 19
SignPath Pharma Inc - Locations And Subsidiaries 20
Head Office 20
Appendix 21
Methodology 21
Coverage 21
Secondary Research 21
Primary Research 21
Expert Panel Validation 21
Contact Us 22
Disclaimer 22
List of Tables
SignPath Pharma Inc, Key Information 4
SignPath Pharma Inc, Key Facts 4
SignPath Pharma Inc - Pipeline by Indication, 2014 6
SignPath Pharma Inc - Pipeline by Stage of Development, 2014 7
SignPath Pharma Inc - Monotherapy Products in Pipeline, 2014 8
SignPath Pharma Inc - Phase I, 2014 9
SignPath Pharma Inc - Preclinical, 2014 10
SignPath Pharma Inc - Discovery, 2014 11
SignPath Pharma Inc - Pipeline by Route of Administration, 2014 17
SignPath Pharma Inc - Pipeline by Molecule Type, 2014 18
SignPath Pharma Inc - Recent Pipeline Updates, 2014 19
List of Figures
SignPath Pharma Inc - Pipeline by Top 10 Indication, 2014 6
SignPath Pharma Inc - Pipeline by Stage of Development, 2014 7
SignPath Pharma Inc - Monotherapy Products in Pipeline, 2014 8
SignPath Pharma Inc - Pipeline by Top 10 Route of Administration, 2014 17
SignPath Pharma Inc - Pipeline by Top 10 Molecule Type, 2014 18



Renewable Energy Sources Needs To Boost Global Microgrids MarketThe global market for microgrid was worth US$13.3 billion in 2015, and is anticipated to touch an estimate of US$35.2 billion by 2020. Dealers in the market for microgrids are incessantly improving the network hosting&hellipManufacturing Trends In The Coming DaysThe manufacturing industry may be encountering some breezes, but it is irrefutably in the middle of a technological revival that is altering the appearance, structures, and practices of the modern factory. Notwithstanding the jeopardies and&hellipTop 10 Emerging TechnologiesThe World Economic Forum (WEF) and Scientific American lately unveiled the major technological innovation list of the top ten emerging technologies. This list emphasizes on the technological developments which have the supremacy to transform industries,&hellipGlobal Biosimilars Market To Be Led By Novartis by 2020Biologics, which are typically inoculated or injected, are formed in living entities, making them more challenging and costly to manufacture than the usual pills contrived from chemicals. Observing that mock-ups are mostly identical to the&hellipGlobal Thyroid Gland Disorder Treatment Market To Grow SteadilyThe global thyroid gland disorder treatment market was worth US$1.8 billion in 2014 and is projected to reach a market value of US$2.4 billion in 2023 intensifying at a CAGR of 3.1% from 2015 to 2023.  The&hellip

High-speed Data Transmission And High Volume Needs Propel Fiber Optic Connectors Market Fiber optic connectors are a substantial fragment of the global telecommunication industry. Optical fibers are joined using fiber optic connectors, which allow the light conduction between two consecutive optical fibers. An additional im…Extensive Use of Digital Technologies for Diagnostic Applications To Boost Global Optical Imaging Market  The global optical imaging system market is predicted to reach US$ 3 billion by 2024. It is expected to grow at a stable rate and will post a CAGR of more than 8% in the coming years. The growing market infiltration of digital …Foremost Trends In Global Pet Care Market The global pet care market is foretold to improve in the forthcoming years as matched to the preceding years and will showcase better sales in various market segments. It is estimated that the global pet care market will grow at a CAGR o…China To Review Its Food Security Laws  China has arisen as the globe’s firmest developing economy. In addition, China brags about the biggest population pool in the world. In recent times, the one child policy in the republic was terminated. This is anticipated to upsur…Improving Standards Of Living To Boost Global Consumer Durables Market  Consumer durables is a cataloguing of consumer goods that are not essential to be bought very often as they are fashioned in a way so as to last for an extended period of time. Profits in the consumer durables sector were most profoundly…

Global and Europe Bacillus Subtilis Market - Analysis and Outlook to 2022

Published:  28-Jul-2017        Price: US 2960 Onwards        Pages: 127 
This report presents a comprehensive overview of the Bacillus Subtilis market in Europe. This shares the history data information from 2012 to 2016, and forecast from 2017 to 2022. 

This report provides a detailed analysis of the market, its dynamics, structure, characteristics, main players, growth and demand drivers, etc. As a Detailed Analysis report, it covers all details inside analysis and opinion in Bacillus Subtilis industry. 

This report focus Global and Eu......

Asia-Pacific 8-Methoxypsoralen (298-81-7) Market Report 2017

Published:  27-Jul-2017        Price: US 4000 Onwards        Pages: 115 
In this report, the Asia-Pacific 8-Methoxypsoralen (298-81-7) market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split Asia-Pacific into several key Regions, with sales (K MT), revenue (Million USD), market share and growth rate of 8-Methoxypsoralen (298-81-7) for these regions, from 2012 to 2022 (forecast), including
- China
- Japan
......

Global Dental Cements Market Professional Survey Report 2017

Published:  27-Jul-2017        Price: US 3500 Onwards        Pages: 108 
This report studies Dental Cements in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022.

This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering
- 3M
- Kerr Dental
- Shofu
- Ceramir Crown & Bridge
- Dentsply......

2017 Top 5 Physiological Saline Manufacturers in North America, Europe, Asia-Pacific, South America, Middle East and Africa

Published:  27-Jul-2017        Price: US 4960 Onwards        Pages: 153 
"This report will be delivered in 2-3 business days after the order is placed."

The Global Physiological Saline market size will be XX million (USD) in 2022, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022.

This report studies Physiological Saline in Global market, especially in North America, Europe, Asia-Pacific, South America, Middle East and Africa, focuses on the top 5 Physiological Saline Play......

Asia-Pacific Coagulation Reagent Market Report 2017

Published:  27-Jul-2017        Price: US 4000 Onwards        Pages: 107 
In this report, the Asia-Pacific Coagulation Reagent market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split Asia-Pacific into several key Regions, with sales (K Pcs), revenue (Million USD), market share and growth rate of Coagulation Reagent for these regions, from 2012 to 2022 (forecast), including
- China
- Japan
- South Korea......

2017-2022 China Physiological Saline Market Report (Status and Outlook)

Published:  27-Jul-2017        Price: US 3360 Onwards        Pages: 117 
"This report will be delivered in 2-3 business days after the order is placed."

The Physiological Saline market size will be XX million (USD) in 2022 in China, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022.

In China market, the top players include
- Baxter
- Hospira (Pfizer)
- Fresenius Kabi
- BBraun
- Otsuka
- Kelun Group
- CR Double-Cran
- ......

Asia-Pacific Budesonide (BUD) Market Report 2017

Published:  27-Jul-2017        Price: US 4000 Onwards        Pages: 112 
In this report, the Asia-Pacific Budesonide (BUD) market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split Asia-Pacific into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Budesonide (BUD) for these regions, from 2012 to 2022 (forecast), including
- China
- Japan
- South Korea
......

Overactive Bladder Treatment Market by Pharmacotherapy (Anticholinergic- Solifenacin, Oxybutynin, Fesoterodine, Darifenacin; Mirabegron; BOTOX; Neurostimulation), Disease Type (Idiopathic and Neurogenic Bladder Overactivity) - Global Forecast to 2022

Published:  27-Jul-2017        Price: US 5650 Onwards        Pages: 236 
“Global overactive bladder treatment market is projected to grow at a CAGR of 2.9%.”
The global overactive bladder treatment market is estimated to grow at a CAGR of 2.9% from 2017 to 2022, to reach USD 4.19 billion by 2022. The key factors driving the growth of this market include the rising prevalence of overactive bladder (OAB) coupled with the growing geriatric population and rising neurological disorders, namely, Parkinson’s Disease (PD), stroke......

Asia-Pacific Cardiovascular and Soft Tissue Repair Patches Market Report 2017

Published:  27-Jul-2017        Price: US 4000 Onwards        Pages: 124 
In this report, the Asia-Pacific Cardiovascular and Soft Tissue Repair Patches market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split Asia-Pacific into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Cardiovascular and Soft Tissue Repair Patches for these regions, from 2012 to 2022 (forecast), including......


SERVICES

Value for Money
We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.

Ever Growing Inventory
Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.

One Stop Solution
Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.

Dedicated Client Engagement
Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.

Saving Time and Efforts
Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.

Payment Flexibility
Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.

Post-Purchase Research Support
Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements.
Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )

Ad Hoc
Pay - as - you - go / Bucket Subscriptions
Fixed Cost for #of reports
Customize / Personalize as per your needs


















 Avail upto 25% Discount on below Publisher Reports.
   
Azoth Analytics 
Technavio






























SignPath Pharma Inc - Product Pipeline Review - 2015 Trends, Statistics, Segment and Forecasts, Market Size, Share Analysis : Market Research Store



















+49 322 210 92714
                                    (GMT OFFICE HOURS)
                                

+1-855-465-4651
                                    (US/CAN TOLL FREE)
                                

+1-386-310-3803
                                    (US OFFICE NO)
                                
































Home
Categories
Become Publisher
News
About Us
Contact Us



























-Select Category-
Consumer Goods
Food & Beverage
Heavy Industry
Life Sciences
Marketing & Market Research
Public Sector
Service Industries
Technology & Media
Semiconductor
Chemical and Materials
Metallurgical
Market Research




Search












Home >> Life Sciences >> Pharmaceuticals


SignPath Pharma Inc - Product Pipeline Review - 2015



Published: Jul-2015 | Format: PDF | Global Markets Direct | Number of pages: 27 | Code: MRS - 28949



Report Details
Table Of Content
Inquiry For Buying
Request Sample



SignPath Pharma Inc - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘SignPath Pharma Inc - Product Pipeline Review - 2015’, provides an overview of the SignPath Pharma Inc’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of SignPath Pharma Inc’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of SignPath Pharma Inc including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of SignPath Pharma Inc’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the SignPath Pharma Inc’s pipeline products

Reasons to buy

- Evaluate SignPath Pharma Inc’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of SignPath Pharma Inc in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the SignPath Pharma Inc’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of SignPath Pharma Inc and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of SignPath Pharma Inc
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of SignPath Pharma Inc and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues


Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
SignPath Pharma Inc Snapshot 5
SignPath Pharma Inc Overview 5
Key Information 5
Key Facts 5
SignPath Pharma Inc - Research and Development Overview 6
Key Therapeutic Areas 6
SignPath Pharma Inc - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
SignPath Pharma Inc - Pipeline Products Glance 10
SignPath Pharma Inc - Clinical Stage Pipeline Products 10
Phase I Products/Combination Treatment Modalities 10
SignPath Pharma Inc - Early Stage Pipeline Products 11
IND/CTA Filed Products/Combination Treatment Modalities 11
Preclinical Products/Combination Treatment Modalities 12
SignPath Pharma Inc - Drug Profiles 13
Liposomal Curcumin 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
EU-8120 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
Liposomal PLGA Curcumin 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
Nanocurcumin 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
SignPath Pharma Inc - Pipeline Analysis 19
SignPath Pharma Inc - Pipeline Products by Target 19
SignPath Pharma Inc - Pipeline Products by Route of Administration 20
SignPath Pharma Inc - Pipeline Products by Molecule Type 21
SignPath Pharma Inc - Pipeline Products by Mechanism of Action 22
SignPath Pharma Inc - Recent Pipeline Updates 23
SignPath Pharma Inc - Dormant Projects 24
SignPath Pharma Inc - Locations And Subsidiaries 25
Head Office 25
Appendix 26
Methodology 26
Coverage 26
Secondary Research 26
Primary Research 26
Expert Panel Validation 26
Contact Us 26
Disclaimer 27 
List of Tables
SignPath Pharma Inc, Key Information 5
SignPath Pharma Inc, Key Facts 5
SignPath Pharma Inc - Pipeline by Indication, 2015 7
SignPath Pharma Inc - Pipeline by Stage of Development, 2015 8
SignPath Pharma Inc - Monotherapy Products in Pipeline, 2015 9
SignPath Pharma Inc - Phase I, 2015 10
SignPath Pharma Inc - IND/CTA Filed, 2015 11
SignPath Pharma Inc - Preclinical, 2015 12
SignPath Pharma Inc - Pipeline by Target, 2015 19
SignPath Pharma Inc - Pipeline by Route of Administration, 2015 20
SignPath Pharma Inc - Pipeline by Molecule Type, 2015 21
SignPath Pharma Inc - Pipeline Products by Mechanism of Action, 2015 22
SignPath Pharma Inc - Recent Pipeline Updates, 2015 23
SignPath Pharma Inc - Dormant Developmental Projects,2015 24 
List of Figures
SignPath Pharma Inc - Pipeline by Top 10 Indication, 2015 7
SignPath Pharma Inc - Pipeline by Stage of Development, 2015 8
SignPath Pharma Inc - Monotherapy Products in Pipeline, 2015 9
SignPath Pharma Inc - Pipeline by Top 10 Route of Administration, 2015 20
SignPath Pharma Inc - Pipeline by Top 10 Molecule Type, 2015 21 

Inquiry For Buying

Please fill your details below, to inquire about this report:
* Indicates required fields






 





Name:






Email:






Phone:






Name of company:






Title/Designation:






Country Name:

-Select Country-
ANDORRA
UNITED ARAB EMIRATES
AFGHANISTAN
ANTIGUA AND BARBUDA
ANGUILLA
ALBANIA
ARMENIA
ANGOLA
ANTARCTICA
ARGENTINA
AMERICAN SAMOA
AUSTRIA
AUSTRALIA
ARUBA
ÅLAND ISLANDS
AZERBAIJAN
BOSNIA AND HERZEGOVINA
BARBADOS
BANGLADESH
BELGIUM
BURKINA FASO
BULGARIA
BAHRAIN
BURUNDI
BENIN
SAINT BARTHÉLEMY
BERMUDA
BRUNEI DARUSSALAM
BOLIVIA, PLURINATIONAL STATE OF
BONAIRE, SINT EUSTATIUS AND SABA
BRAZIL
BAHAMAS
BHUTAN
BOUVET ISLAND
BOTSWANA
BELARUS
BELIZE
CANADA
COCOS (KEELING) ISLANDS
CONGO, THE DEMOCRATIC REPUBLIC OF THE
CENTRAL AFRICAN REPUBLIC
CONGO
SWITZERLAND
CÔTE D'IVOIRE
COOK ISLANDS
CHILE
CAMEROON
CHINA
COLOMBIA
COSTA RICA
CUBA
CAPE VERDE
CURAÇAO
CHRISTMAS ISLAND
CYPRUS
CZECH REPUBLIC
GERMANY
DJIBOUTI
DENMARK
DOMINICA
DOMINICAN REPUBLIC
ALGERIA
ECUADOR
ESTONIA
EGYPT
WESTERN SAHARA
ERITREA
SPAIN
ETHIOPIA
FINLAND
FIJI
FALKLAND ISLANDS (MALVINAS)
MICRONESIA, FEDERATED STATES OF
FAROE ISLANDS
FRANCE
GABON
UNITED KINGDOM
GRENADA
GEORGIA
FRENCH GUIANA
GUERNSEY
GHANA
GIBRALTAR
GREENLAND
GAMBIA
GUINEA
GUADELOUPE
EQUATORIAL GUINEA
GREECE
SOUTH GEORGIA AND THE SOUTH SANDWICH ISLANDS
GUATEMALA
GUAM
GUINEA-BISSAU
GUYANA
HONG KONG
HEARD ISLAND AND MCDONALD ISLANDS
HONDURAS
CROATIA
HAITI
HUNGARY
INDONESIA
IRELAND
ISRAEL
ISLE OF MAN
INDIA
BRITISH INDIAN OCEAN TERRITORY
IRAQ
IRAN, ISLAMIC REPUBLIC OF
ICELAND
ITALY
JERSEY
JAMAICA
JORDAN
JAPAN
KENYA
KYRGYZSTAN
CAMBODIA
KIRIBATI
COMOROS
SAINT KITTS AND NEVIS
KOREA, DEMOCRATIC PEOPLE'S REPUBLIC OF
KOREA, REPUBLIC OF
KUWAIT
CAYMAN ISLANDS
KAZAKHSTAN
LAO PEOPLE'S DEMOCRATIC REPUBLIC
LEBANON
SAINT LUCIA
LIECHTENSTEIN
SRI LANKA
LIBERIA
LESOTHO
LITHUANIA
LUXEMBOURG
LATVIA
LIBYA
MOROCCO
MONACO
MOLDOVA, REPUBLIC OF
MONTENEGRO
SAINT MARTIN (FRENCH PART)
MADAGASCAR
MARSHALL ISLANDS
MACEDONIA, THE FORMER YUGOSLAV REPUBLIC OF
MALI
MYANMAR
MONGOLIA
MACAO
NORTHERN MARIANA ISLANDS
MARTINIQUE
MAURITANIA
MONTSERRAT
MALTA
MAURITIUS
MALDIVES
MALAWI
MEXICO
MALAYSIA
MOZAMBIQUE
NAMIBIA
NEW CALEDONIA
NIGER
NORFOLK ISLAND
NIGERIA
NICARAGUA
NETHERLANDS
NORWAY
NEPAL
NAURU
NIUE
NEW ZEALAND
OMAN
PANAMA
PERU
FRENCH POLYNESIA
PAPUA NEW GUINEA
PHILIPPINES
PAKISTAN
POLAND
SAINT PIERRE AND MIQUELON
PITCAIRN
PUERTO RICO
PALESTINIAN, STATE OF
PORTUGAL
PALAU
PARAGUAY
QATAR
RÉUNION
ROMANIA
SERBIA
RUSSIAN FEDERATION
RWANDA
SAUDI ARABIA
SOLOMON ISLANDS
SEYCHELLES
SUDAN
SWEDEN
SINGAPORE
SAINT HELENA, ASCENSION AND TRISTAN DA CUNHA
SLOVENIA
SVALBARD AND JAN MAYEN
SLOVAKIA
SIERRA LEONE
SAN MARINO
SENEGAL
SOMALIA
SURINAME
SOUTH SUDAN
SAO TOME AND PRINCIPE
EL SALVADOR
SINT MAARTEN (DUTCH PART)
SYRIAN ARAB REPUBLIC
SWAZILAND
TURKS AND CAICOS ISLANDS
CHAD
FRENCH SOUTHERN TERRITORIES
TOGO
THAILAND
TAJIKISTAN
TOKELAU
TIMOR-LESTE
TURKMENISTAN
TUNISIA
TONGA
TURKEY
TRINIDAD AND TOBAGO
TUVALU
TAIWAN, PROVINCE OF CHINA
TANZANIA, UNITED REPUBLIC OF
UKRAINE
UGANDA
UNITED STATES MINOR OUTLYING ISLANDS
UNITED STATES
URUGUAY
UZBEKISTAN
HOLY SEE (VATICAN CITY STATE)
SAINT VINCENT AND THE GRENADINES
VENEZUELA, BOLIVARIAN REPUBLIC OF
VIRGIN ISLANDS, BRITISH
VIRGIN ISLANDS, U.S.
VIET NAM
VANUATU
WALLIS AND FUTUNA
SAMOA
YEMEN
MAYOTTE
SOUTH AFRICA
ZAMBIA
ZIMBABWE





How can we help you?











Refresh



captcha:





 


Submit







Request Sample

Please fill your details below, to receive sample report:
* Indicates required fields






 





Name:






Email:






Phone:






Name of company:






Title/Designation:






Country Name:

-Select Country-
ANDORRA
UNITED ARAB EMIRATES
AFGHANISTAN
ANTIGUA AND BARBUDA
ANGUILLA
ALBANIA
ARMENIA
ANGOLA
ANTARCTICA
ARGENTINA
AMERICAN SAMOA
AUSTRIA
AUSTRALIA
ARUBA
ÅLAND ISLANDS
AZERBAIJAN
BOSNIA AND HERZEGOVINA
BARBADOS
BANGLADESH
BELGIUM
BURKINA FASO
BULGARIA
BAHRAIN
BURUNDI
BENIN
SAINT BARTHÉLEMY
BERMUDA
BRUNEI DARUSSALAM
BOLIVIA, PLURINATIONAL STATE OF
BONAIRE, SINT EUSTATIUS AND SABA
BRAZIL
BAHAMAS
BHUTAN
BOUVET ISLAND
BOTSWANA
BELARUS
BELIZE
CANADA
COCOS (KEELING) ISLANDS
CONGO, THE DEMOCRATIC REPUBLIC OF THE
CENTRAL AFRICAN REPUBLIC
CONGO
SWITZERLAND
CÔTE D'IVOIRE
COOK ISLANDS
CHILE
CAMEROON
CHINA
COLOMBIA
COSTA RICA
CUBA
CAPE VERDE
CURAÇAO
CHRISTMAS ISLAND
CYPRUS
CZECH REPUBLIC
GERMANY
DJIBOUTI
DENMARK
DOMINICA
DOMINICAN REPUBLIC
ALGERIA
ECUADOR
ESTONIA
EGYPT
WESTERN SAHARA
ERITREA
SPAIN
ETHIOPIA
FINLAND
FIJI
FALKLAND ISLANDS (MALVINAS)
MICRONESIA, FEDERATED STATES OF
FAROE ISLANDS
FRANCE
GABON
UNITED KINGDOM
GRENADA
GEORGIA
FRENCH GUIANA
GUERNSEY
GHANA
GIBRALTAR
GREENLAND
GAMBIA
GUINEA
GUADELOUPE
EQUATORIAL GUINEA
GREECE
SOUTH GEORGIA AND THE SOUTH SANDWICH ISLANDS
GUATEMALA
GUAM
GUINEA-BISSAU
GUYANA
HONG KONG
HEARD ISLAND AND MCDONALD ISLANDS
HONDURAS
CROATIA
HAITI
HUNGARY
INDONESIA
IRELAND
ISRAEL
ISLE OF MAN
INDIA
BRITISH INDIAN OCEAN TERRITORY
IRAQ
IRAN, ISLAMIC REPUBLIC OF
ICELAND
ITALY
JERSEY
JAMAICA
JORDAN
JAPAN
KENYA
KYRGYZSTAN
CAMBODIA
KIRIBATI
COMOROS
SAINT KITTS AND NEVIS
KOREA, DEMOCRATIC PEOPLE'S REPUBLIC OF
KOREA, REPUBLIC OF
KUWAIT
CAYMAN ISLANDS
KAZAKHSTAN
LAO PEOPLE'S DEMOCRATIC REPUBLIC
LEBANON
SAINT LUCIA
LIECHTENSTEIN
SRI LANKA
LIBERIA
LESOTHO
LITHUANIA
LUXEMBOURG
LATVIA
LIBYA
MOROCCO
MONACO
MOLDOVA, REPUBLIC OF
MONTENEGRO
SAINT MARTIN (FRENCH PART)
MADAGASCAR
MARSHALL ISLANDS
MACEDONIA, THE FORMER YUGOSLAV REPUBLIC OF
MALI
MYANMAR
MONGOLIA
MACAO
NORTHERN MARIANA ISLANDS
MARTINIQUE
MAURITANIA
MONTSERRAT
MALTA
MAURITIUS
MALDIVES
MALAWI
MEXICO
MALAYSIA
MOZAMBIQUE
NAMIBIA
NEW CALEDONIA
NIGER
NORFOLK ISLAND
NIGERIA
NICARAGUA
NETHERLANDS
NORWAY
NEPAL
NAURU
NIUE
NEW ZEALAND
OMAN
PANAMA
PERU
FRENCH POLYNESIA
PAPUA NEW GUINEA
PHILIPPINES
PAKISTAN
POLAND
SAINT PIERRE AND MIQUELON
PITCAIRN
PUERTO RICO
PALESTINIAN, STATE OF
PORTUGAL
PALAU
PARAGUAY
QATAR
RÉUNION
ROMANIA
SERBIA
RUSSIAN FEDERATION
RWANDA
SAUDI ARABIA
SOLOMON ISLANDS
SEYCHELLES
SUDAN
SWEDEN
SINGAPORE
SAINT HELENA, ASCENSION AND TRISTAN DA CUNHA
SLOVENIA
SVALBARD AND JAN MAYEN
SLOVAKIA
SIERRA LEONE
SAN MARINO
SENEGAL
SOMALIA
SURINAME
SOUTH SUDAN
SAO TOME AND PRINCIPE
EL SALVADOR
SINT MAARTEN (DUTCH PART)
SYRIAN ARAB REPUBLIC
SWAZILAND
TURKS AND CAICOS ISLANDS
CHAD
FRENCH SOUTHERN TERRITORIES
TOGO
THAILAND
TAJIKISTAN
TOKELAU
TIMOR-LESTE
TURKMENISTAN
TUNISIA
TONGA
TURKEY
TRINIDAD AND TOBAGO
TUVALU
TAIWAN, PROVINCE OF CHINA
TANZANIA, UNITED REPUBLIC OF
UKRAINE
UGANDA
UNITED STATES MINOR OUTLYING ISLANDS
UNITED STATES
URUGUAY
UZBEKISTAN
HOLY SEE (VATICAN CITY STATE)
SAINT VINCENT AND THE GRENADINES
VENEZUELA, BOLIVARIAN REPUBLIC OF
VIRGIN ISLANDS, BRITISH
VIRGIN ISLANDS, U.S.
VIET NAM
VANUATU
WALLIS AND FUTUNA
SAMOA
YEMEN
MAYOTTE
SOUTH AFRICA
ZAMBIA
ZIMBABWE





How can we help you?











Refresh



captcha:





 


Submit











Related Reports


Global and Europe BCG Vaccine Market - Analysis and Outlook to 2022

Jul-2017 | EU Research | Pages : 124 | Code : MRS-152913 | 2960
                    
This report presents a comprehensive overview of the BCG Vaccine market in Europe. This shares the history data information from 2012 to 2016, and forecast from 2017 to 2022. This report provides a detailed analysis of the market, its dynamics, structure, characteristics, main players, growth and demand drivers, etc. As a Detailed Analysis report, it covers all details inside analysis and opinion in BCG Vaccine industry. This report focus Global and Europe market, it covers details playe Read more




Global Onychomycosis (Tinea Unguium) Drug Detailed Analysis Report 2017-2022

Jul-2017 | Detailed Analysis Research | Pages : 118 | Code : MRS-152903 | 3250
                    
This report splits Onychomycosis (Tinea Unguium) Drug by Product Drug Form, by Product Usage Type. This shares the history data information from 2012 to 2016, and forecast from 2017 to 2022. And this report mainly introduces volume and value market share by players, by regions, by product type, by consumers and also their price change details. As a Detailed Analysis report, it covers all details inside analysis and opinion in Onychomycosis (Tinea Unguium) Drug industry. This report fo Read more




Life Science Analytics - Global Market Outlook (2017-2023)

Jun-2017 | Stratistics MRC | Pages : 159 | Code : MRS-152851 | 4150
                    
According to Stratistics MRC, the Global Life Science Analytics market is expected to grow from $9.45 billion in 2016 to reach $25.60 billion by 2023 with a CAGR of 15.3%. Some of the factors propelling the market growth are raising demand for analytics in sales and marketing applications, increasing need of these solutions especially in clinical trials and improvements in technological advancements. However lack of skilled professionals, huge implementation costs, and financial limitations Read more




Chronic Kidney Disease (CKD) Drugs - Global Market Outlook (2017-2023)

Jul-2017 | Stratistics MRC | Pages : 160 | Code : MRS-152825 | 4150
                    
According to Stratistics MRC, the Global Chronic Kidney Disease (CKD) Drugs market is expected to grow from $12.87 billion in 2016 to reach $16.13 billion by 2023 with a CAGR of 3.2%. Drivers that are shaping the global market include, growing incidences of chronic kidney diseases, rise in aged population, rising incidence of diabetes and obesity related disorders, significant unmet requirements and beneficial reimbursement policies. On the other hand, factors such as intense competition fr Read more




Acaricides - Global Market Outlook (2017-2023)

Jul-2017 | Stratistics MRC | Pages : 167 | Code : MRS-152794 | 4150
                    
According to Stratistics MRC, the Global Acaricides Market is expected to grow from $270.12 million in 2016 to reach $412.10 million by 2023 with a CAGR of 6.2%. High demand for meat, dairy products and crops, growth in crop protection industry and rise in productivity are some of the factors propelling the market growth. However, increase in cost, alternative acaricides sources and regulatory restrictions are the factors suppressing the market. On the other hand, expansion of bioactive aca Read more




Global and United States Bacillus Subtilis Depth Research Report 2017-2022

Jul-2017 | United States Research | Pages : 108 | Code : MRS-152793 | 3190
                    
This report mainly introduces volume and value market share by players, by regions, by product type, by consumers and also their price change details. As a Depth Research Report, it covers all details inside analysis and opinion in Bacillus Subtilis industry. This report focus United States market, it covers details players regions product type and other details as following: Major Companies ?Bayer (Germany) ?BASF (Germany) ?Tonglu Huifeng (China) ?Kernel Bio-tech (China) ?W Read more




Global Bacterial Vaginosis Drug Market Rport 2017

Jun-2017 | BisReport  | Pages : 134 | Code : MRS-152720 | 2350
                    
Global Bacterial Vaginosis Drug Market Report 2017 Full Report: 2350 Multi License (Section): 4700 Section Price: As below Page: 115 Chart and Figure: 124 Publisher: BisReport Delivery Time: 24 hour Contact: sales@bisreport.com Phone: +86-18701006088 With the slowdown in world economic growth, the Bacterial Vaginosis Drug industry has also suffered a certain impact, but still maintained a relatively optimistic growth, the past four years, Bacterial Vaginosis Drug market size to maintain  Read more




Global Alzheimer's Disease Drug Market Rport 2017

Jun-2017 | BisReport  | Pages : 127 | Code : MRS-152719 | 2350
                    
Global Alzheimer’s Disease Drug Market Report 2017 Full Report: 2350 Multi License (Section): 4700 Section Price: As below Page: 115 Chart and Figure: 124 Publisher: BisReport Delivery Time: 24 hour Contact: sales@bisreport.com Phone: +86-18701006088 With the slowdown in world economic growth, the Alzheimer’s Disease Drug industry has also suffered a certain impact, but still maintained a relatively optimistic growth, the past four years, Alzheimer’s Disease Drug market size to maintain  Read more




Global Protein Powder Detailed Analysis Report 2017-2022

Jul-2017 | Detailed Analysis Research | Pages : 153 | Code : MRS-152586 | 3250
                    
This report mainly introduces volume and value market share by players, by regions, by product type, by consumers and also their price change details. As a Detailed Analysis report, it covers all details inside analysis and opinion in Protein Powder industry. This report splits Protein Powder market Price, Size, First Speciality, Second Speciality, Protein Powder Flavors, which covers the history data information from 2012 to 2016 and forecast from 2017 to 2022. This report focus Glob Read more




Opioid-Induced Constipation (OIC) - Pipeline Review, H2 2017

Jul-2017 | Global Markets Direct | Pages : 63 | Code : MRS-152442 | 2000
                    
Opioid-Induced Constipation (OIC) - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Opioid-Induced Constipation (OIC) - Pipeline Review, H2 2017, provides an overview of the Opioid-Induced Constipation (OIC) (Toxicology) pipeline landscape. Opioids are effective pain relievers, but often have the side effect of constipation. These medicines affect the gastrointestinal tract in a variety of ways. Opioids increase the amo Read more








Payment Mode




Single User  | $(USD)1500








Multi User | $(USD)3000








Corporate User  | $(USD)4500













Latest Report


2017 Global Non-Slip Epoxy Glass Flake Paint Market Research Report


2017 Global Parking Sensors Market Research Report


2017 Global Nitrogen Oxide Sensor Market Research Report


2017 Global Nuclear Density Gauge Market Research Report


2017 Global Automotive Interior Materials Market Research Report

View More



Latest News


Global Chitosan Market Set for Rapid Growth, To Reach USD 4.74 Billion by 2021

Zion Market Research has published a new report titled Chitosan Market for Water Treatment, Biomed



Development of e-commerce to Reshape Global Mobile Hotspot Router Market

Mobile hotspot is a popular feature on smart phones that provide wireless internet access on many 



Global Carotenoids Market Is Expected To Reach Around USD 1.52 Billion in 2021

Zion Market Research has published a new report titled Carotenoids Market by Type (Astaxanthin, Be



Soaring Demand from Food & Beverages Industry to Act as Prime Driving for Ascorbic Acid Market, Reports Zion Market Research

Ascorbic acid is extensively available in nature, mostly rich in leafy vegetables and fresh fruits



Global Energy Management System (EMS) Market Is Set for a Rapid Growth and is Expected to Reach USD 63,161.5 million by 2021

Zion Market Research has published a new report titled Energy Management System Market (EMS) by So


View More














Single User | $(USD)1500
View Pricing 













Find Help

How to Order
Disclaimer 
FAQs
Return Policy
Sitemap



Our Company

About Us
Terms and Conditions
Privacy Policy



We accept the following payment methods






© 2016 - 2017 Market Research Store - Market Research Reports 









